UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION
RESEARCHER
TYPE
SPONSOR
2005 FUNDING
TITLE
Allergy & Immunology
Kanani
Clinical Trial
Bayer Healthcare
$
Allergy & Immunology
Stark
Clinical Trial
ZLB Behring AG
$
Effects of IgG Trough Levels on Quality of Life and Clinical Indices of Patients Receiving IVIG for 123,000.00 Hypogammaglobulinemia An Open Study to Evaluate the Safety and Efficacy of IVIG-F10 In Patients With Primary Immunodeficiency Disease 14,213.00 PID (ZLB04-005CR)
Cardiology Cardiology
Bernstein Bernstein
Grant Clinical Trial
Various Pharmaceutical Companies MRC: Clinical Trials
$ $
107,394.00 Cardiology Research 3,600.00 Heart Outcomes Prevention Trial (HOPE)
Cardiology
Bernstein
Clinical Trial
Eli Lilly Canada Inc.
$
Cardiology
Bernstein
Clinical Trial
Servier Canada Inc.
$
Cardiology
Bernstein
Clinical Trial
Pfizer Canada Inc.
$
Cardiology
Bernstein
Clinical Trial
Vasogen Inc.
$
IMAGINE: Ischemia management with Accupril post bypass graft via inhibition of converting enzyme. An evaluation of 20,394.00 the effect of 12 to approximately 24 months treatment with Quinapril 40mg QD post CABG surgery Ismetic events Protocol 0101: Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled Study of Efficacy & Safety of Immune Modulation Therapy in Improving Walking Distance in Patients with Intermittent Claudication Secondary to 14,575.00 PAD Protocol 0202 (ACCLAIM): Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Assess the Effects of Immune Modulation Therapy (IMT) on Mortality and Morbidity in Patients with Chronic Heart 27,586.00 Failure
48,902.00 Ruth Study, Raloxifene Hydrochloride or placebo in postmenopausal women at risk for major cardiovascular events CL3-16257-056: Effects of Ivabradine on Cardiovascular Events in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction. A Three-year Randomized, Double-blind, Placebo-controlled International 15,135.00 Multicentre Study
Cardiology
Bernstein
Clinical Trial
Vasogen Inc.
$
Cardiology
Bernstein
Clinical Trial
Hamilton Health Sciences Corporation
$
Cardiology Cardiology Cardiology Cardiology Cardiology
Bernstein Bernstein Bernstein Bernstein Buller
Clinical Trial Clinical Trial Grant Clinical Trial Contract
Sanofi-Synthelabo Canada Inc. CIHR: Health Research Institutes Heart & Stroke Foundation of Canada National Institutes of Health Guidant Corporation
$ $ $ $ $
9,654.00 ONTARGET: Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial AMADEUS 64720: Multicentre, Randomized, Open-label, Assessor-blind, Non-inferiority Study Comparing the Efficacy & Safety of Once-weekly Subcutaneous Idraparinux (SanOrg34006) with Adjusted-dose Oral Vitamin K Antagonists in 6,160.00 the Prevention of… 400.00 AF-CHF: Atrial Fibrillation and Congestive Heart Failure 60,000.00 Magnesium Study 14,530.00 STICH: Surgical Treatment for Ischemic Heart Failure 5,928.00 In Vivo Evaluation of the WTO guide wire, a Non-GLP Study
Cardiology
Buller
Clinical Trial
NIH (US): Research Grant
$
14,417.00 Total Occlusion Study of Canada-2 (TOSCA-2) An Angiographic Sub-study of the Occluded Artery Trial (OAT)
Cardiology Cardiology
Buller Buller
Clinical Trial Clinical Trial
Procter & Gamble Company (US) National Heart, Lung and Blood Institute
$ $
Cardiology
Buller
Clinical Trial
$
Cardiology Cardiology
Buller Buller
Clinical Trial Clinical Trial
Boston Scientific Corporation Canadian Vigour Centre, University of Alberta evYsio Medical Devices ULC
Cardiology
Buller
Clinical Trial
Arginox Pharmaceuticals, Inc.
$
Cardiology
Buller
Clinical Trial
Cordis Corporation
$
3,300.00 Protocol CVC1002: The WEST Study: Which Early ST Elevation Myocardial Infarction Therapy 500.00 Evaluation of a Novel Guidewire Exchange Catheter ARG-101-061503 SHOCK 2: Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Nitric Oxide Synthase Inhibition with Ng Monomethyl-L-Arginine (L-NMMA) in Patients with Cardiogenic Shock Complicating Acute 1,798.00 Myocardial Infarction… 1525004 ACROSS-Cypher: Approaches to Chronic Occlusions with Sirolimus Stents-Cypher: Total Occlusion Study 3,444.00 of Coronary Arteries…
$
Zomaxx II Study - A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxx Drug Eluting Coronary Stent System as compared to the Taxus Express Paclitaxel-eluting Stent in de-novo Coronary Artery 3,000.00 Lesions
Cardiology
Buller
Agreement
Cardiology
Carere
Grant
UBC Department of Medicine
Abbott Vascular Devices St. Luke's - Roosevelt Institute for Health Sciences
$ $
$
2003056 APEX-AMI: Multicentre, Randomized, Double-blind, Parallel-group, Placebo-controlled study of Pexelizumab 8,800.00 in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention 28,833.00 OAT: Occluded Artery Trial - Total Occlusion Study of Canada 2 (TOSCA 2) Sub-study TAXUS ATLAS: Multicentre Single-arm Study of the TAXUS Liberte-SR Stent for the Treatment of Patients with De 27,766.00 Novo Coronary Artery Lesions
13,709.00 Open Artery Trial (OAT II)
210
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION Cardiology
RESEARCHER Carere
TYPE Agreement
SPONSOR MRC: Clinical Trials
Cardiology Cardiology Cardiology Cardiology Cardiology
Chan Chan Chan Fung Fung
Clinical Trial Grant Grant Grant Contract
Pfizer Canada Inc. H&SFBC: Research H&SFBC: Research Vancouver Coastal Health Authority Vancouver Biotech Ltd.
Cardiology
Fung
Clinical Trial
CV Therapeutics Inc.
2005 FUNDING TITLE $ 4,539.00 Clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) Trial Modulation of arterial reactivity using Amlodipine and Atorvastatin measured by ultrasound examination STUDY $ 31,949.00 A0531006 $ 57,960.00 Aging, cardiac risk factors, endothelial function and endothelial progenitor cells $ 9,974.00 Lipid lowering effects on LDL subclasses and endothelial function $ 544,705.00 Interventional Cardiology Research: Clinical Research Coordinators Positions $ 1,250.00 CRA: Study of a whole blood test device for human cardiac troponin I CVT 5131: A Phase III Randomized, Double-blind Study of Intravenous CVT-3146 vs Adensocan in Patients $ 19,431.00 Undergoing Stress Myocardial Perfusion Imaging
Cardiology
Fung
Clinical Trial
The Medicines Company
$
Cardiology
Fung
Clinical Trial
American BioScience, Inc.
$
Cardiology
Fung
Clinical Trial
Velocimed, Inc.
$
Cardiology
Fung
Clinical Trial
Sanofi-Synthelabo Canada Inc.
$
Protocol 0231-001 (The Proximal Trial) Proximal Protection During Saphenous Vein Graft Intervention Using the 8,155.00 Proxis Embolic Protection System: A Randomized Prospective Multicentre Clinical Trial Protocol EFC 3197 (OASIS 5): International, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Fondaparinux vs. Enoxaparin in the Acute Treatment of Unstable Angina/Non ST-Segment Elevation MI Acute 44,050.00 Coronary Syndromes AGI-1067-042 ARISE: Multicentre, Double-blind, Randomized, Placebo-controlled Trial to Study the Reduction of Vascular Inflammation & Coronary Atherosclerosis with AGI-1067 a V-Protectant Reduces Cardiovascular Events in 17,914.00 Patients with Coronary…
Cardiology
Gin
Clinical Trial
Atherogenics, Inc.
$
Cardiology
Gin
Clinical Trial
Sanofi-Synthelabo Canada Inc.
$
Cardiology
Gin
Clinical Trial
Procter & Gamble, Canada
$
Cardiology Cardiology
Hamburger Humphries
Clinical Trial Grant
$ $
Cardiology Cardiology
Humphries Humphries
Grant Grant
Atherogenics, Inc. H&SFBC: Research MSFHR: Career Investigator Program CISCH-067(01-2) CIHR: Health Research Institutes
Cardiology
Ignaszewski
Clinical Trial
Pfizer Inc.
$
Cardiology
Ignaszewski
Clinical Trial
Novartis Pharmaceuticals Canada Inc.
$
$ $
TMC-BIV-02-08 Acuity: Randomized Comparison of Angiomax (bivalirudin) vs. Lovenox/Clexane (Enoxaparin) in 106,435.00 Patients Undergoing Early Invasive Management for Acute Coronary Syndrome Without ST-segment Elevation 81,401.00 CVR001-0 SNAPIST: Phase II Safety Study of Systemic Nanoparticle Paclitaxel (AVI-007) for In Stent Restenosis
12,694.00 Protocol EFC4912 (ACTIVE): Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events PREMIER Study: Multicentre Randomized Double-Blind Parallel-Group Placebo-Controlled Study of a 200 mg Oral Dose of PG-116800 Given Twice Daily for 90 Days to Patients Following Acute Myocardial Infarction with Post1,950.00 Treatment Follow-up Safety and efficacy of AGI-1067 as an agent to prevent post angioplasty restenosis and coronary atherosclerosis 29,663.00 progression (CART II) 166,992.00 Magnesium for the prevention of atrial arrhythmias after cardiac surgery (M-PAACS) 80,000.00 Secondary Prevention - The Gap Between Evidence and Practice 18,500.00 GENESIS - Sex and Gender Differences in Cardiovascular Disease Phase 3 multi-center, double-blind, randomized, parallel group evaluation of the fixed combination torcetrapib/atorvastatin, administered orally, once daily(QD) compared with atorvastatin alone on the occurrence of 120,936.00 major cardiovascular events… A Six-month, Multicenter, Randomized, Open-label Study of the Safety, Tolerability and Efficacy of Two Neoral(R) 1,900.00 Doses in addition to Certican(TM) and Steroids in de novo Heart Transplant Recipients
Cardiology
Ignaszewski
Clinical Trial
Fujisawa Canada Inc.
$
5,083.00
Cardiology
Ignaszewski
Clinical Trial
Novartis Pharmaceuticals Canada Inc.
$
17,964.00
Cardiology
Jue
Clinical Trial
Aventis Pharmaceuticals Inc.
$
2,220.00
Cardiology
Jue
Grant
Canadian Institutes of Health Research
$
18,734.00
Cardiology
Jue
Clinical Trial
Novartis Pharmaceuticals Canada Inc.
$
UBC Department of Medicine
Clinical and Laboratory Evaluation of Cellular Rejection, Myocyte Growth, Repair and Oxidative Stress following de novo Cardiac Transplant: A comparison between Tacrolimus and Cyclosporine-based Immunoprophylactic Regimens with Mycophenolic A Three-month, Multicenter, Open-label, Single-arm Pilot study of the Renal Safety of Everolimus in Addition to Neoral in Cardiac Transplant Recipients The Synergy Trial: A Prospective, Randomized, Open-label, Multicentre Study in Patients Presenting with Acute Coronary Syndromes (ACS). Protocol DC-452-003: ASTRONOMER - The Effect of Cholesterol Lowering on Progression of Aortic Stenosis in Patients with Mild to Moderate Aortic Stenosis
VALIDD - CVAL489AUS52: Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Effect of 3,500.00 the Angitensin II Antagonist Valsartan on Diastolic Function in Patients With Hypertension and Diastolic Dysfunction
211
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION Cardiology Cardiology
RESEARCHER Jue Kerr
TYPE Clinical Trial Grant
SPONSOR Various Sources University of Ottawa
2005 FUNDING TITLE $ 18,515.00 Echo Research Account $ 11,500.00 Resynchronization/Defibrillation for Advanced Heart Failure SHOCK: Should we emergently revascularize occluded coronaries for cardiogenic shock: An international $ 707.00 randomized trial of emergently PTCA/CABG Phase II Placebo-controlled, Double-blind, Dose-ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300mg OD, with Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients with Recent Atrial $ 5,350.00 Fibrillation…
Cardiology
Kerr
Clinical Trial
Various US Companies
Cardiology
Kerr
Clinical Trial
Cardiology
Mancini
Contract
Sanofi-Synthelabo Canadian Vigour Centre, University of Alberta
$
$ $ $
13,000.00 The WEST Study: Which Early ST Evaluation Myocardial Infarction Therapy?
Cardiology Cardiology Cardiology
Mancini Mancini Mancini
Agreement Grant Clinical Trial
NIH (US) OAT 99-01, 1R01-HL62511-01A1 in collaboration with The Maryland Medical Research Institute Various Sources International Medical Innovations Inc.
Cardiology
Ramanathan
Clinical Trial
Arginox Pharmaceuticals, Inc.
$
Cardiology
Ramanathan
Clinical Trial
Harvard University
$
Cardiology
Ricci
Clinical Trial
Eli Lilly Canada Inc.
$
Cardiology
Ricci
Clinical Trial
EV3 Inc.
$
Cardiology
Ricci
Clinical Trial
National Institutes of Health
$
21,238.00 Occluded Artery Trial (OAT) - Angiographic Core 352,693.00 Carotid studies 12,000.00 To Determine the Relationship Between Skin Cholesterol Values and Cardiovascular Disease Markers A Phase III International, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Nitric Oxide Synthase Inhibition with Tilarginine Acetate Injection in Patients with 3,570.00 Cardiogenic… Study to Assess the Risk Factor Associated with Premature Atherosclerosis and Coronary Artery Disease in People of 60,000.00 South Asian Descent (STAAR) H7T-MC-TAAL (TIMI 38): A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are 29,774.00 to Undergo Percutaneous Coronary Intervention/ TIMI 38 G980258 - X-TRACTION: X-SIZER Treatment for Reduction of Angiographically Confirmed Thrombus and Infarction 34,846.00 Occurrence Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease 46,299.00 (FREEDOM) 01-01-TL-OPI-516 - PERISCOPE: Double-blind, Randomized, Comparator-controlled Study in Subjects with Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCL vs. Glimepiride on the Rate of Progression of Coronary 164,606.00 Atherosclerotic Disease 2,975.00 SAVE PACe - Search AV Extension for Promoting Atrioventricular Conduction 17,775.00 WEST: Which Early ST Elevation Myocardial Infarction Therapy?
Cardiology Cardiology Cardiology
Saw Tung Webb
Clinical Trial Clinical Trial Clinical Trial
Takeda Global Research and Development Medtronic (USA) Hoffmann-La Roche Ltd (Canada)
$ $ $
Cardiology
Webb
Clinical Trial
NMT Medical, Inc.
$
Cardiology
Webb
Clinical Trial
Sanofi-Synthelabo Canada Inc.
$
Cardiology
Webb
Clinical Trial
Arginox Pharmaceuticals, Inc.
$
Cardiology Cardiology
Webb Webb
Clinical Trial Clinical Trial
Velocimed, Inc. Boston Scientific Corporation
$ $
Cardiology
Webb
Clinical Trial
Boston Scientific Corporation
$
Cardiology
Webb
Clinical Trial
Boston Scientific Corporation
$
Critical Care
Chittock
Grant
Critical Care
Chittock
Clinical Trial
UBC Department of Medicine
Various Sources: CIHR & Society of Critical Care Medicine CIHR: Randomized Controlled Trials (Clinical Trials)
$ $
A prospective, multicenter, randomized, controlled trial to evaluate the safety and efficacy of the Starflex (R) septal 2,390.00 closure system vs. best medical therapy in patients with a stroke and/or transient ischemic attack due to presumed… An international, randomized study evaluating the efficacy and safety of fondaparinux sodium vs. control therapy and glucose insulin-potassium infusion vs. control in a broad range of patients with ST segment elevation acute 14,231.00 myocardial… SHOCK-2 Trial: A randomized, double-blind, placebo-controlled, dose-ranging study of Nitrous Oxide Synthase inhibition with Ng-Monomethyl-L-Arginine (L-NMMA) in patients with cardiogenic shock complicating acute myocardial 1,819.00 infarction… Proximal Protection during Saphenous Vein Graft Intervention using the Proxis TM Embolic Protection System: A 18,293.00 Randomized, Prospective, Multicenter, Clinical Trial (PROXIMAL) 87,500.00 Fellowship Funding FLAME TRIAL: The FiLterWire EZ System Used in the Treatment of an Acute Myocardial Infarction for Embolic 1,218.00 Protection: A prospective, multi-center, randomized study TAXUS II: A double-blind, controlled study of the safety and performance of the NIRx(TM) Paclitaxel-coated conformer 383.00 coronary stent 237,680.00 Various Clinical Trials Agreements 6,400.00 VASST: Randomized, Controlled Trial of Vasopressin vs. Norepinephrine in Septic Shock
212
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION Critical Care
RESEARCHER Dhingra
TYPE Grant Clinical Trial
SPONSOR UBC Department of Medicine Canadian Intensive Care Foundation and University of Ottawa
Critical Care
Dhingra
$
CIHR: Partnership for Health System Improvement PHE-78693 in collaboration with Dalhousie University & Queen's University
$
Critical Care
Dodek
Grant
Critical Care
Dodek
Grant
Critical Care Critical Care
Dodek Dodek
Grant Grant
Critical Care
Dorscheid
Agreement
Critical Care
Dorscheid
Grant
NIH (US): Research Grant In Collaboration with: University of Chicago MSFHR: Career Investigator Program C1SCH-31(01-2)
Critical Care
Fenwick
Clinical Trial
Chiron Corporation
Critical Care
Fenwick
Clinical Trial
Critical Care
Fenwick
Critical Care
Keenan
2005 FUNDING TITLE $ 15,000.00 Survival Using Glucose Algorithm Regulation (SUGAR) Trial
HC/CIHR: Research Project $ MSFHR: HSPR Operating Grants Program LOI $ Canadian Institutes of Health Research $
1,500.00 (FINESS) Fluids in Early Severe Sepsis
18,988.00 Relationship between organizational culture and family satisfaction in critical care Improving the quality and end of life care in Canada: Understanding the perspectives of seriously ill patients and their 8,600.00 caregivers 130,360.00 HSPRSN Investigative Teams development grant - Intensive Care Unit Patient Safety Team 5,000.00 Survival Using Flucose Algorithm Regulation-Sugar Trial
$
47,724.00 Eosinophil-Airway Epithelial Fas-Fasl Interactions
$
$
60,000.00 Airway epithelial injury as a result of corticosteroid-induced apoptosis A Phase III, Multicenter, Randomized, Placebo-controlled, Double-blind, Three-arm Study to Evaluate the Safety and Efficacy of Tifacogan (recombinant tissue factor pathway inhibitor) Administration in Subjects with Severe Community 10,706.00 Acquired Pneumonia
Novo-Nordisk
$
F7CBI-1600: Randomized, Double-blind, Placebo-controlled, Multicentre, Dose Escalation Study to Evaluate the 1,771.00 Safety and Preliminary Efficacy of Recombinant Factor VIIa (novoSevenNiaStase) in Subjects with Brain Contusions
Clinical Trial
Novo-Nordisk
$
Clinical Trial
GlaxoSmithKline Inc.
$
F7CBI-1587:Multicentre Observational Study to Evaluate the Incidence and Magnitude of Hemorrhagic Progression of 7,207.00 Cerebral Contusions and the Identification of Important Safety Issues Following Traumatic Brain Injury Prospective, randomized, double-blind, placebo-controlled, dose-ranging, multi-center study of the safety and efficacy of three days continuous intravenous infusion of GR270773 in the treatment of suspected or confirmed gram-negative 5,000.00 severe sepsis in adults
Critical Care
Keenan
Clinical Trial
Theravance Inc.
$
6,465.00
Critical Care Critical Care
Keenan Keenan
Clinical Trial Clinical Trial
Chiron Corporation University of B.C.
$ $
13,998.00 3,800.00
Critical Care
Keenan
Clinical Trial
Wyeth Canada
$
1,500.00
Critical Care
Keenan
Clinical Trial
Leo Pharma Inc.
$
700.00
Critical Care
Keenan
Clinical Trial
McMaster University
$
17,000.00
Critical Care
Keenan
Clinical Trial
$
4,900.00
Critical Care Critical Care Critical Care
Keenan Ronco Russell
Clinical Trial Clinical Trial Contract
London Health Sciences Research Inc. Queen's University & Kingston General Hospital MRC: Clinical Trials MRC/CIHR: Opportunity Program
$ $ $
4,300.00 9,000.00 7,500.00
Critical Care
Russell
UBC Department of Medicine
Clinical Trial
Chiron Corporation
$
Phase III, randomized, double-blind parallel-group, multinational trial of Intravenous Telavancin vs. Vancomycin for Treatment of hospital-acquired pneumonia with a focus on patients with infections due to methicillin-resistant staphylococcus aureus Phase III, multicenter, randomized, placebo-controlled, double-blind, three-arm study to evaluate the safety and efficacy of tigacogin A randomized controlled trial of vasopressin vs. norepinephrine in septic shock Phase III, multicentre, randomized, double-blind comparative study of the efficacy and safety of tigecycline vs imipenem/cilastatin for the treatment of subjects with nosocomial pneumonia A phase III study with freeze dried HL 10, three dosages of 200mg/kg Ideal Body Weight vs. standard therapy in ALI/ARDS Patients The primary objective of this study is to determine the effect of LOVS, in comparison to pressure and volume limited ventilation, alone, on all-cause 28-day mortality for patients with acute lung injury The Sepsis Treatment and Response (STAR) Registry is a prospective, observational study. The primary objective is to describe the outcome of patients who develop severe sepsis A randomized trial of empiric broad-spectrum antibiotics and invasive diagnostic techniques in the setting of ventilatorassociated pneumonia LOVS: A Randomized Trial of a Lung Open Ventilation Strategy in Acute Lung Injury (MRC #78042) A randomized trial of a lung open ventilation strategy in acute lung injury
A phase III, multicentre, randomized, placebo-controlled, double-blind, three-arm study to evaluate the safety and efficacy of Tifacogin (recombinant tissue factor pathway inhibitor) administration in subjects with severe community12,943.00 acquired pneumonia
213
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION
RESEARCHER
TYPE
Critical Care
Russell
Grant
Critical Care
Russell
Grant
Critical Care
Russell
Grant
Critical Care Critical Care Critical Care
Walley Walley Walley
Contract Grant Grant
Critical Care
Walley
Grant
Critical Care
Walley
Grant
SPONSOR MSFHR: Junior Graduate Studentship Award ST-JGS 222(03-1) CLIN MSFHR: Postdoctoral Trainee Fellowship ST-PDF 259(03-1)CLIN (Fellow: Manocha, Sanjay) CIHR: Randomized Controlled Trials (Clinical Trials) Sirius Genomics Inc. H&SFBC: Research H&SFBC: Research Heart & Stroke Fdn Cda: Research Fellowship - Bateman, Ryon MSFHR: Distinguished Scholar Award CIDSH-73(02-1)
Critical Care
Walley
Grant
Critical Care Critical Care
Walley Walley
Grant Grant
MSFHR: Junior Graduate Studentship Award ST-JGS 219(03-1) CLIN (Fellow: Shaw, David) MSFHR: Postdoctoral Trainee Fellowship ST-PDF 147(03-1)BM (Fellow: Bateman, Ryon) CIHR: Operating Grant MOP-53051
Critical Care
Walley
Grant
CIHR: Operating Grant MOP 57774 Canadian Dermatology Foundation: Research Grant Canadian Dermatology Foundation: Research Grant Canadian Diabetes Association: Charles H. Best Fund/Grant-in-Aid BCRICWH Canadian Dermatology Foundation: Research Grant National Alopecia Areata Fdn (US)
2005 FUNDING $
$
39,000.00 Clinical Outcomes of Acute Lung Injury: Role of Cytokine Gene Polymorphisms as Predictors
$
145,952.00 A randomized controlled trial of vasopressin vs. norepinephrine in septic shock
$ $ $
CRA: Association of the influence of inflammatory mediator polymorphisms with outcomes in systemic inflammatory 79,520.00 response syndrome (SIRS) and multiple organ system failure (MOSF) 80,178.00 Mechanism of myocardial dysfunction during sepsis 363,880.00 Genetic determinants of cognitive dysfunction following cardiopulmonary bypass
$ $
$
$ $ $
38,000.00 Mechanism of myocardial dysfunction in sepsis Translating mechanistic understanding of the systemic inflammatory response syndrome (SIRS) to clinical practice via 120,000.00 genomics
3,125.00 Clinical outcomes of cardiac surgery are influenced by genetics of inflammatory mediators
12,778.00 Mechanism of myocardial dysfunction in sepsis 109,661.00 Myocardial Dysfunction Induced by ICAM-1 binding Influence of polymorphisms in coagulation pathway in inflammatory mediator genes on phenotype post80,952.00 cardiopulmonary bypass surgery
$
Further application of cutaneous, genetic, and immunologic testing for the management of abacavir hypersensitivity 20,000.00 syndrome
$
25,000.00 Skin immunization for tolerance induction
$ $
74,976.00 Toll-like Receptors in Type I Diabetes Mellitus 80,682.00 BCRICWH: Investigatorship Award
$ $
20,000.00 Optimizing vaccine efficiency through the topical use of immunomodulators 40,896.00 Screening for cytoxic T lymphocyte epitopes in alopecia areata
Dermatology
Crawford
Grant
Dermatology
Dutz
Grant
Dermatology Dermatology
Dutz Dutz
Grant Grant
Dermatology Dermatology
Dutz Dutz
Grant Grant
Dermatology Dermatology
Dutz Dutz
Grant Grant
Dermatology Dermatology Dermatology Dermatology
Dutz Dutz Dutz Ho
Grant Grant Grant Grant
JDFI: Research 4-2004-783 in collaboration w/ Simon Fraser University 3M Pharmaceuticals 1533-RESI CIHR/Strategic: Request for App. NSM66117 in collaboration w/ The Institute of Musculoskeletal Health and Arthritis (CIHR) CIHR: Operating Grant MOP - 67186 CIHR: Operating Grant MOP-69004 Canadian Dermatology Foundation
Dermatology
Ho
Clinical Trial
Abbott Laboratories
$
Dermatology
Ho
Clinical Trial
Centocor Inc.
$
Dermatology
Ho
Clinical Trial
Fujisawa Healthcare Inc.
$
UBC Department of Medicine
TITLE Genetic Determinants of the Host Response to Infection in Critically ill Adults with Systemic Inflammatory Response 1,917.00 Syndrome
$ $
159,390.00 Beta-cell apoptosis and autoimmunity network (b-CAAN) 9,819.00 Cellular immune response to a topical immune modulator
$ $ $ $
34,974.00 114,332.00 127,958.00 25,000.00
RFA: New Discoveries - High Risk Grant: Tolerance induction by skin immunization Modifying islet antigen presentation to treat diabetes Chemo-immunotherapy and CTL priming to treat malignant melanoma Role of ING2 in nucleotide excision repair of UV-damaged DNA Protocol M02-529: Phase II Multicenter Extension Study of the Safety & Efficacy of Adalimumab (D2E7) in Subjects 1,886.00 with Moderate to Severe Chronic Plaque Psoriasis C0168T44: Phase III Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and 31,883.00 Safety… Protocol FG 03-0-166: Phase 3 Randomized, Double-blind Study Comparing Twice Daily Tacrolimus Cream 0.03% vs 17,643.00 Cream Vehicle in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects
214
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION
RESEARCHER
TYPE
SPONSOR
2005 FUNDING
Dermatology
Ho
Clinical Trial
Novartis Pharmaceuticals Canada Inc.
$
Dermatology
Ho
Clinical Trial
Novartis Pharmaceuticals Canada Inc.
$
Dermatology
Ho
Clinical Trial
Fujisawa Canada Inc.
$
Dermatology
Ho
Clinical Trial
Fujisawa Canada Inc.
$
Dermatology Dermatology Dermatology Dermatology Dermatology
Ho Li Li Li Li
Clinical Trial Grant Grant Grant Grant
Abbott Laboratories, Limited (Canada) Canadian Dermatology Foundation NCIC/CCS: Research Scientist 012443 NCIC: Research Grant 01424 NCIC: Research Grant 014029
$ $ $ $ $
Dermatology
Li
Grant
Dermatology
Li
Grant
Dermatology
Li
Grant
MSFHR: Doctoral Trainee Research Award STPHD63020 (Fellow: Campos, Eric) MSFHR: Junior Graduate Studentship Award ST-JGS 31(03-1)BM (Fellow: Karst, Alison) Canadian Dermatology Fdn: Research Grant
TITLE
CASM981C2439: A 4-week randomized, multicenter, parallel-group, open-label, vehicle-controlled study followed by an 8-week observational period to evaluate the safety and efficacy of concomitant use of ASM 981 (pimecrolimus) 27,578.00 cream 1% (BID) ... CASM981C2442: A 12-week multicenter study consisting of a 6-week, double-blind, randomized vehicle- controlled parallel group phase followed by a 6-week open-label phase to assess the safety & efficacy of Elidel Cream 1% in mild 47,762.00 to moderate… PRO 002B: An open-label, long-term follow-up study to evaluate the safety of topically applied Tacrolimus Ointment 5,113.00 for the treatment of atopic Dermatitis in pediatric patients FG-506-06-33: Long-Term Non-Comarative Study to Evaluate the Safety and Efficacy of Tacrolimus Ointment in 5,600.00 Paediatric Patients Protocol M03-658: Multicenter, Open-label, Continuation Study in Moderate to Severe Chronic Plaque Psoriasis 6,454.00 Subjects Who Completed a Preceding Psoriasis Clinical Study with Adalimumab 25,000.00 Identification of genetic differences in primary and metastatic melanomas 89,840.00 Role of p33ing1 in repair of uv-damaged DNA 123,264.00 Functional role of p33ING1 phosphorylation in cellular stress response to DNA damage 108,312.00 Enhancement of melanoma chemosensitivity by adenoviral delivery of PUMA and Apaf-1
$
2,500.00 Functional role of p33ING1 phosphorylation in cellular stress response to DNA damage
$
1,875.00 Enhancement of melanoma chemosensitivity by adenoviral delivery of PUMA
$
50,000.00 The Role of Tumor Suppressor PTEN in Melanoma Chemosensitivity
Dermatology
Li
Grant
Dermatology
Li
Grant
Dermatology
Li
Grant
Dermatology Dermatology
Li Li
Grant Grant
MSFHR: Junior Graduate Studentship Award ST-JGS-049(04-1)BM (Fellow: Kuo, Wei Hung) MSFHR: Senior Graduate Studentship Award ST-SGS-162(04-1_BM (Fellow: Kin Cheung Ng) CIHR: Doctoral Research Awards MDR75845 (Fellow: Karst, Alison) NCIC/CCS: Student Travel Award (Fellow: Karst, Alison) CIHR: Operating Grant MOP-74512
Dermatology Dermatology
Lui Lui
Clinical Trial Clinical Trial
Astellas Pharma Canada, Inc. Biogen Idec, Inc.
$ $
1,400.00 2005 AACR annual meeting: Anaheim, CA "Puma in human melanoma: a prognostic marker and therapeutic target" 89,473.00 Role of ING2 in Repair of UV-damaged DNA and Melanoma Pathogenesis Protocol FG 03-0-171: Phase 3 Long-term, Open-label Study to Evaluate the Safety of Once Daily 0.3% Tacrolimus 24,579.00 Gel in the Treatment of Psoriasis 32,000.00 AWARE: Amevive Wisdom Acquired from Real-Time Evidence
Dermatology
Lui
Clinical Trial
Biogen Idec, Inc.
$
Protocol C-733: An Open-Label Multicentre Study to Evaluate the Safety & Tolerability of Repeat Courses of 27,610.00 Intramuscular Administration of Alefacept (LFA-3/IgG1 Fusion Protein) in Patients with Chronic Plaque Psoriasis
Dermatology
McElwee
Grant
Canadian Dermatology Foundation
$
Dermatology Dermatology
McElwee McElwee
Grant Grant
$ $
Dermatology
McElwee
Grant
Canadian Dermatology Foundation North American Hair Research Society National Alopecia Areata Foundation: Research Grant
35,000.00 Natural Killer (NK) Cell Dysfunction in Human and Rodent Model Alopecia Areata Identification of hair follicle derived mesenchymal cells as a source of progenitor cells for skins, appendages and non25,000.00 skin organs 6,566.00 The Action of Cardiotrophin and Related IL-6 Superfamily Members on Hair Growth
$
34,782.00 Hair Follicle Immune Privilege and Changes in Alopecia Areata
Dermatology
McElwee
Grant
Dean of Medicine: Spring Start Up Funds
$
10,000.00 Mechanisms of hair disease
UBC Department of Medicine
$
2,500.00 ING1b promotes chromatin relaxation for nucleotide excision repair of UV-induced DNA lesions
$
2,500.00 Role of integrin-linked kinase in human melanoma invasion
$
1,000.00 Enhancement of Melanoma Chemosensitivity by Adenoviral Delivery of PUMA
$ $
215
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION
RESEARCHER
TYPE
SPONSOR Department of Medicine Academic Enhancement Fund: Academic Scholar Program
Dermatology
McElwee
Grant
Dermatology
McElwee
Grant
Dermatology
McLean
Dermatology
2005 FUNDING
$
TITLE
15,000.00 The significance of macrophage stimulating protein and its regulators in hair growth and androgenetic alopecia Treatment of inflammatory skin diseases with adoptive cellular gene therapy using hair follicle dermal papilla derived 46,993.00 cells as vectors
$
Grant
CIHR: Special Projects NSM-72203 Canadian Dermatology Foundation: Research Grant
Rivers
Clinical Trial
Novartis Pharmaceuticals Canada Inc.
$
Dermatology
Rivers
Clinical Trial
Serono Inc.
$
Dermatology
Shapiro
Clinical Trial
Isotechnika, Inc.
$
Dermatology Dermatology
Shapiro Shapiro
Clinical Trial Clinical Trial
Leo Pharma Inc. Leo Laboratories Canada Ltd.
$ $
Dermatology
Shapiro
Clinical Trial
$
Dermatology
Shapiro
Grant
$
15,000.00 The Action of IL-6 Cytokine Superfamily Members on Hair Growth
Dermatology
Tang
Grant
QLT Photo Therapeutics Inc. Canadian Dermatology Foundation: Research Grant Canadian Dermatology Foundation: Research Grant
24979: A Multicentre, Randomized, Double-blind, Placebo-controlled Phase III Study of Subcutaneously Administered 23,616.00 Onercept in the Treatment and Re-Treatment of Subjects with Moderate to severe Plaque Psoriasis ISA04-03: Phase III Randomized, Multicentre, Double-blind, Placebo-controlled Study of ISA247 in Plaque Psoriasis 267.00 Patients MBL 0405 INT: Calcipotriol Plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the 22,976.00 Gel Vehicle Calcipotriol in the Gel Vehicle and the Gel Vehicle Alone in Scalp Psoriasis 1,500.00 Protocol MBL 0401 INT: Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis Protocol T0074 AGA 002: Phase II Treatment Optimization Study of Photodynamic Therapy for Androgenetic Alopecia 9,769.00 with Topical QLT0074
$
20,000.00 Roles of osteopontin in melanoma invasion
Dermatology Dermatology
Tang Zeng
Grant Grant
$ $
25,000.00 A Potential Key Regulator of Melanoma Progression: Transforming Growth Factor Beta-Stimulated Clone 22 (TSC-22) 208,104.00 Raman spectroscopy for non-invasive diagnosis: Applications in skin cancer detection
Dermatology
Zeng
Grant
Canadian Dermatology Foundation National Cancer Institute of Canada Canadian Dermatology Foundation: Research Grant
$
Dermatology
Zeng
Grant
$
Dermatology
Zeng
Grant
$
10,000.00 Subsurface in vivo raman spectroscopy and fluorescence spectroscopy for skin research and diagnosis
Dermatology Dermatology
Zhao Zhou
Grant Grant
CIHR: Operating Grant ITM-66116 Canadian Dermatology Foundation: Research Grant Canadian Dermatology Foundation: Research Grant Canadian Dermatology Foundation
25,000.00 Rapid raman spectroscopy for non-invasive skin cancer diagnosis Visible to near infrared fluorescence excitation-emission matrix (EEM) spectroscopy system for skin characterization 30,572.00 and diagnosis
$ $
25,000.00 Colorimetric and spectroscopic monitoring of post inflammatory pigmentation 50,000.00 Gene Expression Markers of Metastatic Melanoma: A Functional Characterization
Dermatology
Zhou
Grant
CIHR: Institute Operating Grant IMH-73565
$
100,000.00 Endothelin-3 in Malignant Melanoma
Endocrinology Endocrinology
Dawson Dawson
Clinical Trial Clinical Trial
MRC: Operating Grant Hoechst-Roussel
$ $
Endocrinology
Elliott
Clinical Trial
National Institutes of Health
$
200.00 The HOPE Study: Heart Outcomes Prevention Evaluation 910.00 The HOPE Study: Heart Outcomes Prevention Evaluation ACCORD Eye Study: Substudy of the Action to Control Cardiovascular Disease in Diabetes Study Control 182,470.00 Cardiovascular Disease in Diabetes Study
Endocrinology Endocrinology
Endocrinology
Elliott Elliott
Elliott
UBC Department of Medicine
Clinical Trial Clinical Trial
Clinical Trial
Novartis Pharmaceuticals Canada Inc. Amgen Inc.
Boehringer Ingelheim (Canada) Ltd.
$
10,000.00 Optical Technique for Skin Roughness Measurements CASM981M2301: A Six-week, Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Elidel Cream 1% in Patients With Mild to Moderate Chronic Hand Dermatitis 27,060.00 Followed by a 6 Week Open...
$ $
NAVIGATOR: Multinational, Randomized, Double-blind, Placebo-controlled, Forced-Titration, 2x2 Factorial Design Study of the Efficacy & Safety of Long Term Administration of Nateglinide & Valsartan in the Prevention of Diabetes & 16,319.00 Cardiovascular… 8,100.00 TREAT - 20010184: Trial to Reduce Cardiovascular Events with Aranesp (darbepoetin alfa) Therapy
$
502.397 (AMADEO): Prospective, Randomized, Double-blind, Double-dummy, Forced-titration, Multicentre Parallelgroup, 1-year Treatment Trial to Compare Micardis (Telmisartan) 80mg vs. Cozaar (Losartan) 100mg in Hypertensive 18,366.00 Type 2 Diabetic Patients with…
216
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION
RESEARCHER
TYPE
SPONSOR
Endocrinology
Elliott
Clinical Trial
Eli Lilly Canada Inc.
$
Endocrinology
Elliott
Clinical Trial
Bristol-Myers Squibb, US (Princeton)
$
$ $ $
Endocrinology Endocrinology Endocrinology
Kreisman Prior Prior
Agreement Grant Grant
Endocrinology
Prior
Grant
NIH (US): Research Grant 5R01-DK05835603, PO Q643711310 in collaboration with the U. of Minnesota Donations for Health Science Research Various Sources CIHR/Rx&D: Research Program in collaboration with McGill University
Grant Grant Grant Grant
MSFHR: Doctoral Trainee Research Award 75(02-1)BM (Fellow: Quayle, Steven) Health Canada Health Canada CIHR: Proof of Principle
Endocrinology Endocrinology Endocrinology Endocrinology
Endocrinology Endocrinology
Sadar Sadar Sadar Sadar
Thompson Thompson
Clinical Trial Grant
Novo-Nordisk CIHR: Health Research Institutes
2005 FUNDING
Protocol CV-168062: A Phase III, Randomized, Double-blind, Active-controlled, Multicenter Trial to Evaluate the 3,830.00 Safety and Efficacy of Muraglitazar (BMS-298585) Compared to Pioglitazone in Subjects with Type 2 Diabetes
$
57,499.00 Diabetes Therapy to Improve BMI and Pulmonary Function in CF Subjects with Abnormal Glucose Tolerance 1,465.00 Exercise, Reproduction and Health Research Fund 108,115.00 Centre for Menstrual Cycle and Ovulation Research (CEMCOR) (CAMOS) Canadian Multicentre Osteoporosis Study: A cross-sectional and prospective observational study of bone 44,092.00 density, bone strength and fracture risk
$ $ $ $
625.00 100,000.00 105,000.00 150,000.00
Identification of new targets for the treatment of androgen-independent prostate cancer Androgen Independence Potential New Therapy for Androgen Independence Development of Custom Array for the Prognosis of Prostate Cancer
$ $
A randomized, parallel-group, open-label, multinational trial comparing the safety and efficacy of insulin aspart (NovoRapid) vs. human insulin (Actrapid) used in a multiple injection regimen in the treatment of pregnant women 9,037.00 with… 2,414.00 To Reduce IDDM in Type 1 Diabetes in the Genetically at Risk TRIGR Protocol P02569: PEG-Intron as Maintenance Therapy vs. an Untreated Control Group in Adult Subjects with Compensated Cirrhosis (METAVIR F4) Secondary to Chronic Hep C who have Failed to Respond to Therapy with any 5,118.00 Alpha Interferon + Ribavirin
Gastroenterology
Anderson
Clinical Trial
Schering Canada Inc.
$
Gastroenterology
Anderson
Clinical Trial
Schering Canada Inc.
$
Gastroenterology
Anderson
Clinical Trial
Schering Canada Inc.
$
Gastroenterology Gastroenterology
Anderson Anderson
Clinical Trial Clinical Trial
Bristol-Myers Squibb Co. (Canada) Elan Pharmaceuticals Inc.
$ $
Gastroenterology
Anderson
Clinical Trial
Tillots Pharma AG
$
Gastroenterology
Anderson
Clinical Trial
Centocor Inc.
$
Gastroenterology Gastroenterology
Enns Enns
Clinical Trial Grant
Abbott Laboratories Robarts, J.P. Research Institute
$ $
Gastroenterology
Enns
Clinical Trial
Otsuka America Pharmaceutical Inc.
$
Gastroenterology
Enns
Clinical Trial
Celltech Research Ltd.
$
UBC Department of Medicine
TITLE Protocol H80-MC-GWAP: Safety and Efficacy of Exenatide in Patients with Type 2 Diabetes Using Thiazolidinediones 25,628.00 or Thiazolidinediones and Metformin
Protocol P02370: PEG-Intron Plus Rebetol for the Treatment of Subjects with Chronic Hepatitis C who Failed to 30,125.00 Respond to Previous Combination Therapy (any Alpha Interferon Treatment in Combination with Ribavirin) Protocol P02570: PEG-Intron as Maintenance Therapy vs. an Untreated Control Group for Prevention of Fibrosis in Adult Subjects with Chronic Hep C with Hepatic Fibrosis (METAVIR fibrosis score of F2/F3) Who Have Failed Therapy 3,441.00 with PEG-Intron Protocol AI463049: Long-term Assessment of Treatment Outcomes with Entecavir & Lamivudine for Chronic Hepatitis 1,482.00 B Infection in Patients Who Have Enrolled in Phase III Entecavir Trials 20,077.00 Protocol ELN100226-CD351: Phase III Protocol TP0308: EPIC-2 Phase III Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicentre Study to Assess the Efficacy & Safety of Omega-3 Free Fatty Acids (Epanova) for the Maintenance of Symptomatic 7,401.00 Remission in Subjects… Protocol C0168T37 (ACT 1): Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy 3,825.00 of Infliximab in Patients with Active Ulcerative Colitis A Multi-center, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody 45,806.00 Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Crohn's Disease 2,435.00 Protocol TP#0308 (EPIC-2) Educational Grant A prospective, randomized, double-blinded, placebo(sham)- controlled study to evaluate the safety and effectiveness 576.00 of the Adacolumn Apheresis system for the treatment of moderate to severe ulcerative colitis (512-04-205) A Phase III Multi-national, Multicentre, Open Label 52 Week Safety Study to Assess the Safety of Chronic Therapy with Humanized Anti-TNF PEG Conjugate, CPD870 400mg sc, (dosed 4-weekly to week 48), in the Treatment of 11,530.00 Patients (CDP870-033)…
217
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION
Gastroenterology
Gastroenterology
Gastroenterology
RESEARCHER
Enns
Enns
Enns
TYPE
Clinical Trial
Clinical Trial
Clinical Trial
SPONSOR
Celltech Research Ltd.
AstraZeneca Canada Inc.
Elan Pharmaceuticals Inc.
2005 FUNDING
TITLE
$
A Phase III Multi-national, Multicentre, Double-blind, Placebo-controlled, Parallel-group, 26 week Study to Assess the Maintenance of Clinical Response to Humanized Anti-TNF PEG Conjugate, CDP870 400mg sc (dosed 4-weekly from 5,000.00 weeks 8 to 24)…
$
A Randomized, Double-blind, Multicentre, Dose-finding Phase IIb Study for up to 8 weeks' Treatment with AZD0865 25,50,75mg and esomeprazole 40mg, Given Orally Once Daily for the Healing of Erosive Esophagitis in Adult 450.00 Subjects with GERD…
$
A Phase III Multicenter, Open-label, Long-term Study of the Safety, Tolerability and Efficacy of Intravenous Antegren (Natalizumab) in Crohn's Disease Subjects Who Have Previously Participated in Studies CD251, CD301,CD303, and 19,282.00 CD306 (Substudy)
Gastroenterology
Enns
Clinical Trial
AstraZeneca Canada Inc.
$
Gastroenterology
Enns
Clinical Trial
AstraZeneca Canada Inc.
$
A retrospective review to assess the utilization of intravenous and oral proton pump inhibitors and histamine H2receptor antagonists in Canadian hospitals: DURABLE - Drug Utilization Review of Acid Suppressants for Bleeding 44,940.00 and other Listed... Registry of patients undergoing endoscopic and/or acid suppression therapy and an outcomes analysis for upper 61,204.00 gastrointestinal bleeding (REASON): Retrospective medical chart review in Canadian hospitals
$
A phase III multicenter, randomized, double-blind, parallel-arm 52 week dose comparison study of the efficacy and safety of 25mg QD and 50mg QD of OPC-6535 oral tablets, and 800mg BID of Asacol in the maintenance of 25,882.00 remission in subjects with ulcerative colitis
$
A phase III randomized, placebo-controlled, double-blind, parallel group, multi-centre study to assess the efficacy and safety of Omega-3 free fatty acids (Epanova(TM)) for the maintenance of symptomatic remission in subjects with 10,772.00 Crohn's Disease
$
(M04-691) A multicenter, randomized, double-blind, placebo-controlled study of the human anti-TNF monoclonal antibody adalimumab for the induction of clinical remission in subjects with moderate to severe Crohn's disease who 76,880.00 have lost response…
$
Healing of patients suffering from gastroesophageal reflux esophagitis grade A-D according to Los Angeles classification after treatment with pantoprazole-magnesium dehydrate 80mg in comparison to pantoprazole-sodium 3,411.00 sesquihydrate 40mg A randomized, placebo-controlled, double-blind, multicenter, study to determine the efficacy and safety of VSL #3 probiotic food supplement mixture in prevention of endoscopic recurrence of Crohn's disease after ileo-colonic 8,835.00 surgical resection…
Gastroenterology
Gastroenterology
Gastroenterology
Gastroenterology
Enns
Enns
Enns
Enns
Clinical Trial
Clinical Trial
Clinical Trial
Clinical Trial
Otsuka Maryland Res. Institute, Inc.
Tillotts Pharma AG
Altana Pharma, Inc.
Altana Pharma, Inc.
Gastroenterology
Enns
Grant
University of Alberta
$
Gastroenterology
Enns
Clinical Trial
Searle Canada Ltd.
$
Gastroenterology
Enns
Clinical Trial
Abbott Laboratories
$
Gastroenterology
Enns
Clinical Trial
Abbott Laboratories
$
Gastroenterology
Gray
Clinical Trial
Janssen-Ortho Inc.
$
Gastroenterology
Gray
Clinical Trial
AstraZeneca Canada Inc.
$
Gastroenterology
Gray
Clinical Trial
AstraZeneca Canada Inc.
$
Gastroenterology
Gray
Clinical Trial
AstraZeneca Canada Inc.
$
UBC Department of Medicine
A randomized, double-blind, placebo-controlled study of the efficacy and safety of Celecoxib (SC-58635) in the 3,640.00 prevention of colorectal sporadic adenomatous polyps (EQ4-00-02-018) A Multicenter, Open-label Study of the Human Anti-TNF Monoclonal Adalimumab in Subjects with Crohn's Disease 166,376.00 (M04-690) A multicenter, randomized, double-blind, placebo-controlled study of the human anti-TNF monoclonal antibody adalimumab for the maintenance of clinical remission in subjects with Crohn's disease (Clinical Study Protocol M0214,717.00 0433) RAB-GRD-3001: Randomized, Controlled, Parallel-group Open-label Study to Evaluate Different Dosing Regimens of 1,141.00 Rabeprazole in Controlling Nocturnal Heartburn Symptoms in Patients with Gastroesophageal Reflux Disease D961DL00003: DURABLE - Retrospective Review to Assess the Utilization of Intravenous and Oral Proton Pump Inhibitors and Histamine H2 Receptor Antagonists in Canadian Hospitals - Drug Utilization Review of Acid 30,800.00 Suppressants for Bleeding… D961DL00001 REASON: Registry of Patients Undergoing Endoscopic and/or Acid Suppression Therapy and an 51,600.00 Outcomes Analysis for Upper Gastrointestinal Bleeding: A Retrospective Medical Chart Review in Canadian Hospitals D9770C00012: A Randomized, Double-blind, Multicentre, Dose-finding Phase-IIb Study for up to 8 Weeks Treatment with AZD0865 25,50,75mg and Esomeprazole 40mg Given Orally Once Daily for the Healing of Erosive Esophagitis in 1,800.00 Adult Subjects with...
218
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION
RESEARCHER
TYPE
SPONSOR
2005 FUNDING
TITLE CHTF919A2417: A 4-week Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Study to Evaluate the Efficacy of Tegaserod in Relieving the Symptoms of Female Patients with IBS Excluding Those With Predominant Diarrhea LOGIC: Longitudinal Outcomes Study of GastroIntestinal Symptoms (abdominal pian, bloating, constipation) in Canada Protocol NV-02B-007: Randomized, Double-blind Trial of LdT (Telbivudine) vs. Lamivudine in Adults with Compensated Chronic Hepatitis B NV-02B-010: Phase IIb Extension Study of LdT (Telbivudine) Lamivudine or LdT plus Lamivudine in Subjects with Chronic Hepatitis B Who Have Completed Study NV-02B-003 Endowment for Inflammatory Bowel Disease Research and Education
Gastroenterology
Gray
Clinical Trial
Novartis Pharmaceuticals Canada Inc.
$
7,393.00
Gastroenterology
Gray
Clinical Trial
Novartis Pharmaceuticals Canada Inc.
$
875.00
Gastroenterology
Kwan
Clinical Trial
Idenix Pharmaceuticals, Inc.
$
10,132.00
Gastroenterology Gastroenterology
Kwan Steinbrecher
Clinical Trial Grant
$ $
3,533.00 75,000.00
Gastroenterology Gastroenterology Gastroenterology
Steinbrecher Steinbrecher Steinbrecher
Grant Grant Grant
Idenix Pharmaceuticals, Inc. Geraldine Dow Ferry Endowment Fund Canadian Liver Foundation: Summer Studentship Program (Parhar, Kuljit) CIHR: Operating Grant H&SFBC: Research
$ $ $
Gastroenterology
Steinbrecher
Contract
$
Gastroenterology Gastroenterology
Tai Tai
Grant Grant
$ $
60,000.00 Role of SPARC in Cancer Therapy 5,000.00 The Study of Gastrointestinal Cancers
Gastroenterology
Tai
Grant
$
40,000.00 Genome-wide analysis reveals a novel gene involved in chemotherapy resistance in colorecta cancers
Gastroenterology Gastroenterology
Tai Tai
Grant Grant
Forbes Medi-Tech Inc. MSFHR: Scholar Award CI-SCH-018(041)BIOM Axcan Pharma Inc. CAG/CIHR: New Operating Grant in Gastroenterology MSFHR: Establishment Grant CI-SCH018(04-1)BIOM CIHR: Proof of Principle (PPP-78773)
4,000.00 Regulation of Kupffer Cell Proliferation by Oxidized Low-density Lipoprotein 98,276.00 Pathogenesis of Atherosclerosis 68,421.00 Activation of Macrophage Growth and Survival Pathways by Oxidized LDL Effects of Forbes Compounds on oxLDL Transport, Signalling Pathways in oxLDL-responsive Macrophages, and 12,188.00 Foam Cell Formation/Reversion
Gastroenterology
Yoshida
Clinical Trial
Hoffmann-La Roche Ltd. (Canada)
$
Gastroenterology
Yoshida
Clinical Trial
Schering Canada Inc.
$
Gastroenterology
Yoshida
Clinical Trial
Micrologix Biotech Inc.
$
Gastroenterology
Yoshida
Clinical Trial
Ortho Biotech
$
$ $
37,500.00 Role of SPARC in Cancer Therapy 150,000.00 Development of a Novel Cancer Chemosensitizer BV16209: A Multicenter, Open-label, Expanded Access Program of Pegintereron alfa-2a (ro 25-8310) 7,150.00 Monotherapy and Combination Therapy with Ribavirin (Ro20-9963) in Patients with Chronic Hepatitis C P03685: A Study to Assess Treatment with PEG-Intron and Rebetol in Naive Patients with Genotype 1 Chronic 9,100.00 Hepatitis C and Slow Virological Response HCV-04-001: Phase II Randomized Dose-Ranging Open-Label Multicentre Study to Evaluate the Safety and Efficacy 10,680.00 of Celgosivir for 12 Weeks in Patients with Chronic Hepatitis C Infection HEPC-AN-2: Prospective Study to Evaluate the Hemoglobin Levels of Hepatitis C Virus Infected Patients Receiving 1,006.00 Treatment with Combination Ribavirin/Interferon or Ribavirin/Pegylated Interferon ALFR-HC-03CA: Double Injection, Dose-ranging Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Albuferon (Recombinant Human Albumin-Interferon alfa fusion protein) in Interferon Alfa Naive 142,992.00 Subjects with… ALFR-HC-04: Phase 2b, Randomized, Multi-centre, Active-controlled, Open-label Study to Evaluate the Efficacy and 158,218.00 Safety of Albuferon in Combination with Ribavirin…
Gastroenterology
Yoshida
Clinical Trial
Human Genome Sciences Inc.
$
Gastroenterology
Yoshida
Clinical Trial
Human Genome Sciences Inc.
$
Gastroenterology
Yoshida
Clinical Trial
Human Genome Sciences Inc.
$
Gastroenterology
Yoshida
Clinical Trial
$
General Internal Med.
Hatala
Grant
Idenix Pharmaceuticals, Inc. NBME: Stemmler Fund 48 0405 in collaboration w/ The Royal College of Physicians and Surgeons of Canada, University of Miami, University of Toronto
$
40,178.00 Integrating simulation technology into a national specialty examination in internal medicine
General Internal Med. General Internal Med.
Magee Magee
Grant Grant
MSFHR: Scholar Award CI-SCH-57(02-1) Sunnybrook Health Science Centre
$ $
60,000.00 CHIPS (Control of Hypertension In Pregnancy Study): A Pilot Trial 3,725.00 Control of Hypertension in Pregnancy: Pilot Study
UBC Department of Medicine
ALFR-HC-06: A Randomized, Multi-centre, Open-label Study to Evaluate the Efficacy and Safety of Albuferon in 3,470.00 Combination with Ribavirin in Interferon Alfa Naive Subjects with Chronic Hepatitis C Genotype 2 or 3 NV-02B-011: Randomized, Double-blind Trial of Telbivudine (LdT) vs. Lamivudine in Adults with Decompensated 4,965.00 Chronic Hepatitis B and Evidence of Cirrhosis
219
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION
RESEARCHER
TYPE
$ $
112,340.00 Birth under 29 weeks: Improving outcomes for mothers and babies 17,244.00 IICT: Stop Pain Project - Study l: Assessment of Chronic Pain Burden and Management in Canada
Grant Grant Grant
SPONSOR CIHR: Institute of Human Development and Child/Youth Health MOP-74720 Montreal Heart Institute MSFHR: Senior Scholar Award CI-SSH083(03-1) POPN H&SFBC: Research WGCF: William M. Thurlbeck Prize
General Internal Med. General Internal Med.
Magee Ong-Lam
Grant Clinical Trial
General Internal Med. General Internal Med. General Internal Med.
Palepu Van Eeden Van Eeden
Geriatric Medicine
Adler
2005 FUNDING
$ $ $
100,000.00 Health Research of Vulnerable Urban Populations 57,000.00 Air Pollution Induced Atherogenesis 39,185.00 William Thurlbeck Distinguished Researcher
Grant
Various Sources
$
$
Geriatric Medicine
Beattie
Agreement
CIHR: Operating Grant MOP-57686 in collaboration with the University Health Network
Geriatric Medicine Geriatric Medicine
McElhaney Madden
Clinical Trial Grant
CV Technologies Inc. CVT-E002-2005-2 in collaboration with Capital Health Region CIHR: Operating Grant MOP-77789
$ $
Geriatric Medicine Geriatric Medicine
Meneilly Meneilly
Grant Grant
Novo Nordisk CIHR (* funding is over 5 years)
$ $
Geriatric Medicine
Meneilly
Clinical Trial
Geriatric Medicine
Wong
Grant
Sanofi-Synthelabo Canada Inc. CHARISMA $ VCHRI: VGH & UBC Hospital Foundation In It For Life (Operating) $
TITLE
13,500.00 Research support: Addressing the root causes of genocide
7,740.00 Canadian Alzheimer's disease quality of life study Efficiency and Safety of Cold-fX in the Prevention of Upper Respiratory Tract Infections in Community-Dwelling Adults: 102,113.00 A Multicentre, Randomized, Double-blind, Placebo-controlled Trial 29,646.00 Exercise and cardiovascular control during upright tilt in older adults with Type-2 Diabetes 37,500.00 Effect of GlucoNorm vs. Glyburide on Post-Prandial Hyperglycemia in Elderly Subjects with Type 2 Diabetes 1,159,844.00 Genomics, Genetics and Gerontology Protocol EFC4505 (CHARISMA) - Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, 1,985.00 Management and Avoidance 14,175.00 Functional Performance in the Frail Elderly Population
Hematology
Barnett
Clinical Trial
Hematology
Broady
Grant
Novartis Pharmaceuticals Canada Inc. $ VGH & UBC Hospital Foundation: Mentored Clinician Scientist Comp $
Hematology Hematology
Forrest Hogge
Clinical Trial Grant
Bristol-Myers Squibb Company (Canada) CIHR: Operating Grant IC1 - 70245
$ $
Hematology
Hogge
Clinical Trial
Vion Pharmaceuticals
$
Gleem: An Open-label, Randomized, Multicentre Study Comparing Gleevec (Imatinib) at Doses of 400mg & 800mg in Obtaining Major Molecular Response in Chronic Phase Patients with Philadelphia Chromosome Positive Chronic 4,354.00 Myelogenous… Salary: Generation of antigen specific T regulatory cells for prevention of GVHD through induction of transplantation 50,000.00 tolerance CA180013: Phase II Study to Determine the Activity of BMS-354825 in Subjects with Chronic Phase Philadelphia Chromosome-positive Chronic Myeloid Leukemia who have Disease that is Resistant to High Dose Imatinib Mesylate 78,509.00 (Gleevec)… 22,918.00 Optimization of the use of diptheria toxin-growth factor fusion proteins for treatment of acute leukemia A phase III randomized study of Cloretazine (VNP40101M) and Cytosine Arabinoside (AraC) in patients with acute 8,424.00 myeloid leukemia in first relapse
MSFHR: Postdoctoral Trainee Fellowship STPDF 163021 (Fellow: Hirose, Koichi)
$
32,000.00 Molecular Mechanisms Linking Hox Transcription Factors to Leukemia
$
22,950.00 Novel Strategies for Genetic Modification and Expansion of Hematopoietic Stem Cells
$
20,000.00 Salary: Novel Strategies for Genetic Modification and Expansion of Hematopoietic Stem Cells
Hematology
Humphries
Grant
Hematology
Humphries
Grant
Hematology
Humphries
Grant
Hematology
Humphries
Grant
Hematology
Humphries
Hematology Hematology Hematology Hematology
Grant
MSFHR: Postdoctoral Trainee Fellowship ST-PDF-261(04-1) BM (Fellow: Yung, Eric) CIHR: Postdoctoral Fellowship MFE-78150 (Fellow: Yung, Eric) CIHR: Postdoctoral Fellowship MFE-78150 (Fellow: Yung, Eric) CIHR: Proof of Principle PPP-78774 in collaboration with BC Cancer Agency
$
Humphries
Grant
NCE/Stem Cell Network: Research Grant
$
Humphries Lansdorp Lansdorp
Grant Grant Grant
NCE/Stem Cell Network: Research Grant CFI Infrastructure Operating fund 3857 CFI Infrastructure Operating Fund 3857
$ $ $
UBC Department of Medicine
$
5,000.00 Research Allowance: Novel Strategies for Genetic Modification and Expansion of Hematopoeietic Stem Cells 136,018.00 Novel Agents for Hematopoietic Stem Cell Expansion 74,899.00 HOXB4 Target-genes Specifying Hematopoietic Stem Cell Self-renewal 16,000.00 Cell Therapy for Muscular Disease 110,079.00 CFI Infrastructure Operating Funds: Stem Cell Centre - Operations 6,550.00 CFI Infrastructure Operating Funds: Stem Cell Centre - Centre Share
220
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION
RESEARCHER
TYPE Grant
SPONSOR CIHR/Strategic: Request for Applications (LOI) GMD-77238
Hematology
Lansdorp
Hematology
2005 FUNDING
TITLE
$
Lavoie
Clinical Trial
Hoffman-La Roche Ltd. (Canada)
$
Hematology
Lavoie
Clinical Trial
Merck Frosst Canada & Co.
$
Hematology
Leger
Clinical Trial
BioGenex Laboratories
$
10,000.00 Stem cells for the treatment of bone marrow failure (IICT: SC-04-01) Pharmacodynamic Study of Oral Valganciclovir vs. Intravenous Ganciclovir as Pre-emptive Therapy 25,250.00 in Allogenic Blood and Marrow Transplant with CMV Viremia Single centre clinical experience with Caspofungin alone in combination with other antifungal agents and Cyclosporine 15,000.00 since its approval in Canada (Protocol SM02-04-INT) Safety and Efficacy of XM02 In Patients With Non-hodgkin Lymphoma Receiving 5,132.00 Chemotherapy: Multinational, Multicentre, Randomised, Controlled Study
Hematology
Leger
Clinical Trial
Wyeth-Ayerst Research
$
An Open-label, Randomized, Phase 3 Trial of Intravenous Temsirolimus (CC1-779) at Two Dose Levels Compared to 6,275.00 Investigator's Choice Therapy in Relapsed, Refractory Subjects with Mantle Cell Lymphoma (MCL)
Hematology
Leger
Clinical Trial
Novartis Pharmaceuticals Corporation
$
Hematology Hematology Hematology
Nevill Schrader Schrader
Grant Grant Grant
National Cancer Institute of Canada CIHR Operating Grant MOP-14348 CIHR - Canada Research Chair Tier I
$ $ $
(CSTI571ACA09) An Open-label, Randomized, Multicentre Study Comparing Gleevec (Imatinib) at Doses of 400mg and 800mg in Obtaining Major Molecular Response in Chronic Phase Patients with Philadelphia Chromosome 7,208.00 Positive Chronic Myelogenous Leukemia Phase III Study of Concurrent Tretionoin and Chemotherapy With/Without Arsenic Trioxide (As203) (NSC#706363) as Initial Consolidation Therapy Followed by Maintenance Therapy with Intermittent Tretinoin vs. Intermittent Tretinoin 2,371.00 and… 135,280.00 Molecular characterization of the M-Ras pathway 200,000.00 Canada Research Chair - John Schrader
$
A phase III study of ST1571-106 vs. Interferon-a (IFN-A) combined with Cytarabine (Ara-C0) in patients with newly diagnosed previously untreated Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic 694.00 phase (CML-CP)
Hematology
Shepherd
Clinical Trial
Novartis Pharmaceuticals Canada, Inc.
Hematology
Shepherd
Grant
Hematology
Smith
Grant
BCCDC, BCCWHC, Occupational Health & Safety Agency for Healthcare in BC, and the VCHRI $ Canada Research Chair: Tier II (CIHR) 95001-2053 $
Hematology
Smith
Clinical Trial
AnorMed Inc.
$
Hematology
Sutherland
Clinical Trial
Ortho Biotech
$
Hematology Hematology Hematology
Sutherland Vickars Vickars
Clinical Trial Grant Grant
Janssen-Ortho Inc. Various Sources Canadian Hemophilia Society
$ $ $
Hematology Hematology
Vickars Vickars
Clinical Trial Clinical Trial
Boehringer Ingelheim (Canada) Ltd. Bayer Pharmaceuticals
$ $
19,000.00 Making Healthcare Safer: Evaluate the Online Learning on Infection Control Practices among Healthcare Workers 100,000.00 Canada Research Chair in Cell Therapies for Dr. Clayton Smith AMD3100-C201: Treatment with AMD3100 in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase 8,751.00 the Number of Peripheral Blood Stem Cells When Given a Mobilizing Regimen of G-CSF 26866138-MMY-3001 VELCADE: An International Single-arm Protocol to Provide Expanded Access to VELCADE for Patients with Multiple Myeloma who have Received at Least 2 Previous Lines of Therapy & Are Refractory to or Have 21,198.00 Relapsed After Their… DOXIL-MMY-3001: A Randomized, Controlled Study of DOXIL/CAELYX (doxorubicin HCL liposome injection) and 53,463.00 Velcade (bortezomib) or Velcade Monotherapy for the Treatment of Relapsed Multiple Myeloma 1,000.00 Health-Related Quality of Life in Von Willebrand's Disease 1,000.00 Investigation of Clotting Factor Activity Heterogeneity in Severe Hemophilia A A Phase III Randomized, Parallel-group, Double-blind, Active, Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens (75mg Day 1 Followed by 150mg Day 2 - Completion, and 110mg Day 1 Followed by 94,077.00 220mg Day 2… 3,275.00 Oral Direct Factor Xa Inhibitor BAY 59-7939 In Patients ODIXa-DVT (Study #11223)
Hematology
Vickars
Clinical Trial
Sanofi-Synthelabo Canada Inc.
$
Hematology
Vickars
Clinical Trial
AstraZeneca LP
$
The Van Gogh-DVT Trial: A multicenter, international, randomized, open-label, assessor-blind, non-inferiority study comparing the efficacy and safety of once weekly subcutaneous SanOrg34006 with the combination of(LMW) Heparin 9,720.00 and vitamin K… Optimization of dose of H 376/95 (Oral Direct Thrombin Inhibitor) compared to Warfarin (Coumadin(R)) for the 896.00 prevention of venous thromboembolism following total knee arthroplasty (TKA)
Hematology
Vickars
Clinical Trial
Aventis Pharmaceuticals Inc.
$
An open-label, parallel-group, multi-center study to evaluate the efficacy and safety of enoxaparin vs. unfractionated 4,817.00 heparin in the prevention of venous thromboembolism in patients following acute ischemic stroke
UBC Department of Medicine
221
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION
RESEARCHER
TYPE
Hematology
Vickars
Clinical Trial
Hematology
Vickars
Grant
Infectious Diseases Infectious Diseases Infectious Diseases Infectious Diseases
Av-Gay Av-Gay Av-Gay Av-Gay
Grant Grant Grant Grant
Infectious Diseases Infectious Diseases Infectious Diseases Infectious Diseases
Av-Gay Av-Gay Brunham Brunham
Grant Grant Grant Grant
Infectious Diseases
Cherkasov
Grant
Infectious Diseases
Cherkasov
Grant
Infectious Diseases
Cherkasov
Grant
Infectious Diseases
Cherkasov
Grant
SPONSOR
Bayer Inc. Heart and Stroke Foundation of B.C. & Yukon BC Lung: Project Grant Various Sources BC Lung/CIHR Investigator Various Sources CIHR: New Investigator Award JBH - 47862 (CIHR Scholarship) CIHR Operating Grant MOP - 68857 CIHR Operating Grant: BCCDC Aventis Pasteur: BCCDC CIHR: Postdoctoral Fellowship MFE-76560 (Fellow: Ban, Fuqiang)
Grant
Infectious Diseases
Chow
Grant
Infectious Diseases
Chow
Grant
Infectious Diseases
Chow
Grant
Infectious Diseases
Chow
Grant
Infectious Diseases
Chow
Grant
65952 in collaboration with The Institute of Circulatory & Respiratory Health (Fellow: Heine, Heather)
UBC Department of Medicine
$
10,000.00 (Salary) Design and discovery of novel antimicrobial peptides as effective therapeutics against drug-resistant bacteria
1,042.00 Role of yo T cells and HMG-1 in staphylococcal toxic shock syndrome
Chow
Grant
Molecular Analysis of Mycobacterium Tuberculosis Cell Signaling Elements (Salary) Molecular analysis of Mycobaterium tuberculosis protein kinases and phosphatases Immunobiology of C. trachomatis infection/ Biology of sexually transmitted infection Biological and immunologenic evaluation of C. trachomatis vaccine c. antigens…
$
Infectious Diseases
Chow
25,000.00 95,098.00 133,617.00 484,500.00
9,700.00 In Silico Discovery of Novel Antibiotic Candidates
Grant Grant
Infectious Diseases
$ $ $ $
$
Chow Chow
Grant
Mycothiol mediated innate resistance of mycobacteria to xenobiotics Role of Cholesterol in Tuberculosis Infection Molecular Analysis of Mycobacterium Tuberculosis Cell Signaling Elements (Salary). TB Research - Various sources
Dean of Medicine: Spring Start-up Funds
Infectious Diseases Infectious Diseases
Chow
22,500.00 30,000.00 25,000.00 75,000.00
$
Grant
Infectious Diseases
$ $ $ $
$
2,500.00 Modelling and simulating intra-cellular signalling systems in response to pathogen invasions by semantic networks Quantitative Structure-activity Relationships and Machine Learning Techniques for Identification of Novel 1,000.00 Antimicrobial Agents
Chow
Grant
$
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design, Two-arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip 29,574.00 Replacement Surgery REVERSE (REcurrent VEnous thrombolembolism Risk Stratification Evaluation): A study to develop a clinical 440.00 prediction rule to predict low recurrence risk in patients with idiopathic venous thromboembolism
$
Infectious Diseases
Chow
TITLE
MSFHR: Junior Graduate Studentship Award ST-JGS 26(03-1)BM (Fellow: Hsing, Michael) CIHR: Doctoral Research Awards MDR75875 (Fellow: Fjell, Christopher)
MSFHR: Senior Graduate Studentship Award ST-SGS 104(03-1)BM (Fellow: Kalyan, Shirin) MSFHR: Junior Graduate Studentship Award ST-JGS-050(0401)BM (Fellow: Lam, Grace) MSFHR: Grant-in-Aid OT-GIA-001056 MRC: MD/PhD Studentship MMP-40924 (Fellow: Yong,Paul) MRC: MD/PhD Studentship MMP-38300 (Fellow: Sheldon, Claire) CIHR: MD/PhD Studentship MMP-48141 (Fellow: Tan, Clara) CIHR: MD/PhD Program Studentship MMP58293 (Fellow: Brunham, Liam) CIHR: MD/PhD Program Studentship MMP58313 (Fellow: Coburn, Bryan) CIHR: MD/PhD Program Studentship MMP62317 g p
Infectious Diseases
2005 FUNDING
$ $
An investigation into the effector T regulatory cells on B cell proliferation, immunoglobulin production, and isotype 2,500.00 switching 22,000.00 MD/PhD Program Support
$
1,000.00 Chromosomal abnormalities in reproduction failure and development
$
1,000.00 Neuronal pH: Regulation in health and disease
$
1,000.00 The regulation of transcription factors by integrin kinase in cancer cells
$
1,000.00 Identification and validation of genes modulating LDL cholesterol in humans
$
1,000.00 The pathogenics of salmonella infection
$
$ 65951 in collaboration with: Institute of Circulatory & Respiratory Health (Fellow: Joe, Aaron) $ CIHR: MD/PhD Program Studentship MMP71794 (Fellow: Heslop, Claire) $
500.00 Health Status & access to care among a population of urban youth
1,000.00 Myocardial regeneration with hematopoietic stem cells
1,000.00 Molecular determinants of stem cell trafficking 2,000.00 Biomarkers of oxidative stress: An evaluation of nutrient-gene interactions in coronary artery disease
222
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION
RESEARCHER
TYPE
Infectious Diseases
Chow
Grant
Infectious Diseases Infectious Diseases
Chow Chow
Grant Grant
Infectious Diseases
Grigg
Grant
Infectious Diseases
Grigg
Grant
Infectious Diseases
Grigg
Grant
Infectious Diseases
Grigg
Grant
Infectious Diseases
Grigg
Grant
Infectious Diseases
Grigg
Grant
CFI - Infrastructure Operating Fund 9147 MSFHR: Career Investigator Program (C1SCH-26(01-2) CIHR: New Investigator Award (CIHR Scholarship) MSH-69170 CIHR: Postdoctoral Fellowship IPD-77227 (Fellow: Haile-Merhu, Simon) CIHR: Postdoctoral Fellowship IPD-77227 (Fellow: Haile-Merhu, Simon) NSF: Research Programs OCE-0525750 in collaboration with The U.S. Fish & Wildlife Service
Grant
CIHR: Operating Grant MOP-64388 in collaboration with The Institute of Infection and Immunity (CIHR) pp g
Infectious Diseases
Grigg
SPONSOR
2005 FUNDING
CIHR: MD/PhD Program Studentship MMP71793 (Fellow: Berkhout, Susan) $ Program Grant STI-63299 in collaboration with The Institute of Infection and Immunity (CIHR) $ CIHR: Operating Grant MT-7630 $
Infectious Diseases Infectious Diseases
Grigg Grigg
Grant Grant
Infectious Diseases
Harrigan
Grant
Development/Planning OPD-74422 in collaboration w/ University of California (Davis) VCHRI: Interdisciplinary Grant CIHR: Doctoral Research Awards CGD65030 (Fellow: Brumme, Zabrina)
$
TITLE
2,000.00 Life at the margins: An interdisciplinary analysis of the social determinants of HIV/AIDS and women's health
310,500.00 UBC Training Program for Translational Research in Infectious Diseases 98,278.00 Pathogenesis of staphylococcal toxic shock syndrome 9,125.00 CFI Infrastructure Operating Funds
$
36,500.00 Molecular basis of Toxoplasma Pathogenesis
$
58,500.00 Toxoplasma Surface Antigens and Immunity Research allowance: Regulation of gene expression, genetic diversity, and host-responsiveness of toxoplasma gondii 5,000.00 surface antigens Stipends: Regulation of gene expression, genetic diversity, and host-responsiveness of toxoplasma gondii surface 40,000.00 antigens
$ $
$
Collaborative Research: Identifying the Flow and Control of Pathogens from the Land to the Sea: Tracking 151,800.00 Toxoplasma from Cats to Sea Otters
$
92,816.00 Toxoplasma Surface Antigens and Immunity
$ $
25,000.00 Molecular analysis of a sexual clade of wild Toxoplasma gondii 10,000.00 Serological Strain-typing of Toxoplasma Gondii An investigation into challenges faced in antiretroviral (anti-HIV) therapy today: Human and viral genetic variation, HIV 5,000.00 antiviral resistance and the existence of viral reservoirs
$
Infectious Diseases Infectious Diseases
Harrigan Hmama
Grant Grant
CIHR/Rx&D: Research Program DOP68174 Vancouver Coastal Health Authority
Infectious Diseases
Hmama
Grant
MSFHR: Scholar Award C1-SCH-26(01-2)
Infectious Diseases
Hmama
Grant
Infectious Diseases
Hmama
Grant
$ MSFHR: Postdoctoral Trainee Fellowship ST-PDF-214(04-1)BM (Fellow: Deghmane, Ala-Eddine) $ CIHR: New Investigator Award (CIHR Scholarship) $
Infectious Diseases
Hmama
Grant
CIHR: Postdoctoral Fellowship MFE-70513 (Fellow: Deghmane, Ala-Eddine)
$
Infectious Diseases Infectious Diseases Infectious Diseases
Hmama Hmama Hmama
Grant Grant Grant
BC Lung: Project Grant CIHR: Operating Grant MOP - 67232 TB Veterans - VH Foundation
$ $ $
Identification and characterization of a mycobacterial secreted protein that interact with the actin binding protein 45,000.00 coronin-1/TACO in human macrophages Alteration of the macrophagic endosomal compartment by mycobacteria. Role of the surface glycolipid 30,000.00 lipoarabinomannan and the mycobacterial urease 87,168.00 Identification of mycobacterial factors that inhibit phagosome maturation in human macrophages 10,000.00 TB Research Support
$
A phase III open-label, randomized, active-controlled study assessing the efficacy and safety of T-20/Ro 29/9800 (HIV1 fusion inhibitor) in combination with an optimized background regimen, versus optimized background regimen alone, 10,700.00 in patience…
Infectious Diseases
Montaner
UBC Department of Medicine
Clinical Trial
Hoffman-La Roche Ltd. Canada
$ $
Determination of the Prevalence of RS and X4 HIV, and Associated Risk Factors & Outcomes Among HIV-infected 7,125.00 Individuals Initiating Triple Combination Antiretroviral Therapy in BC 40,000.00 Salary support: Dr. Hmama Molecular study of interaction between Mycobacterium tuberculosis and the macrophage endosomal compartment: 33,750.00 An approach to identify mycobacterial virulence factors Identification and characterization of mycobacterial secreted protein that interacts with the actin-binding protein 7,000.00 conronon-1/TACO in human macrophages 58,500.00 Cell signaling regulating mycobacterial-macrophage interactions
223
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION
RESEARCHER
TYPE
SPONSOR
2005 FUNDING
Infectious Diseases
Montaner
Clinical Trial
Abbott Laboratories
$
Infectious Diseases
Montaner
Clinical Trial
Abbott Laboratories
$
Infectious Diseases
Montaner
Grant
Abbott Laboratories
$
Infectious Diseases Infectious Diseases
Montaner Montaner
Clinical Trial Grant
Boehringer Ingelheim (Canada) Ltd. Various Sources
$ $
IICT: Virological and Clinical Response to Single and Ritonavir-boosted Protease Inhibitor-based HAART within the 69,617.00 Drug Treatment Program of the BC Centre for Excellence in HIV/AIDS An Open Label Safety Study of Tipranavir Co-administered with Low-dose Ritonavir (TPV/r) in Patients with Advanced 1,600.00 HIV-1 Infection and Limited Treatment Options (1182.16) 50,000.00 HIV Trust (A4001027) A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of a Novel CCR5 Antagonist,UK427,857 in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the 34,287.00 Treatment of Antiretroviral…
Infectious Diseases
Montaner
Clinical Trial
Pfizer Canada Inc.
$
Infectious Diseases
Montaner
Clinical Trial
Abbott Laboratories, Limited (Canada)
$
Infectious Diseases
Montaner
Clinical Trial
TheraTechnologies Inc.
$
Infectious Diseases
Montaner
Clinical Trial
Serono Inc.
$
Infectious Diseases Infectious Diseases
Montaner Montaner
Clinical Trial Clinical Trial
Serono Inc. Tibotec Pharmaceuticals Ltd.
$ $
Infectious Diseases Infectious Diseases
Montaner Montaner
Clinical Trial Grant
Infectious Diseases Infectious Diseases Infectious Diseases Infectious Diseases Infectious Diseases Infectious Diseases Infectious Diseases Infectious Diseases Infectious Diseases Infectious Diseases Infectious Diseases
Montaner Montaner Montaner Montaner Montaner Montaner Montaner Montaner Montaner Montaner Nandan
Grant Clinical Trial Grant Clinical Trial Grant Clinical Trial Grant Clinical Trial Grant Clinical Trial Grant
Infectious Diseases Infectious Diseases
Patrick Patrick
Grant Grant
Infectious Diseases Infectious Diseases Infectious Diseases
Phillips Phillips Phillips
Grant Clinical Trial Grant
Infectious Diseases Infectious Diseases
Reiner Reiner
Grant Grant
UBC Department of Medicine
Tibotec Pharmaceuticals Ltd. Ontario HIV Treatment Network Royal Free & University College Medical School GlaxoSmithKline Inc. COL40328 CIHR Operating Grant Abbott Lab. Inc. ACA-AGRE-04-001 Abbott lab. Inc. ACA-CANA-01-015 Abbott Lab. Inc. M01-384 Bristol-Myers Squibb A1455-096 GlaxoSmithKline Inc. Gilead Sciences Bioject Inc. CIHR: Operating Grant MOP 38005 CIHR: Doctoral Research Awards IDR76898 - McCarthy, Sheila Sanofi Pasteur - BCCDC CANFAR: Small Grant GlaxoSmithKline Inc. CIHR - Centre for Excellence MSFHR: SARS Accelerated Vaccine Initiative PJ-SAV-030 CIHR: Operating Grant MOP-8633
TITLE A phase II study of Lopinavir/Ritonavir in combination with Saquinavir Mesylate or Lamivudine/Zidovudine to explore 30,250.00 metabolic toxicities in antiretroviral naïve, HIV-infected subjects A pilot study of a nucleoside analogue reverse transcriptase inhibitor sparing regimen in antiretroviral-naïve, HIV50,000.00 infected patients
67,813.00 IICT: Evaluating treatment options in dyslipidemic HIV+ patients on PI-based HAART: Population-based Analysis Protocol TH9507/III/LIPO/010 - A Phase 3 Multicenter, Double-blind, Placebo-controlled Study Assessing the Efficacy and Safety of a 2mg Doses of TH9507, a Growth Hormone Releasing Factor Analog, in HIV Patients with Excess of 4,681.00 Abdominal… A phase III multi-center, randomized, double-blind, placebo-controlled, parallel group study of the safety and efficacy of serostim (mammalian cell-derived recombinant human growth hormone, r-hGH) in the treatment and maintenance 19,224.00 of Human… (HARS): A phase III, multi-center, open-label, 12-week, follow-up safety and efficacy study of Serostim (mammalian cell-derived recombinant human growth hormone,r-hGH) in subjects with Human Immunodeficiency Virus-associated 1,500.00 adipose… 25,975.00 Protocols TMC 125-C203 and TMC 125-C209
$ $
114,615.00 2,720.00
$ $ $ $ $ $ $ $ $ $ $
565.00 49,403.00 51,560.00 74,328.00 28,000.00 29,875.00 82,500.00 19,735.00 76,000.00 51,886.00 82,162.00
$ $
1,000.00 17,000.00
$ $ $
25,000.00 25,000.00 96,100.00
$ $
A Phase I, Open-label Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of TMC125 Administered as Addon to a Combination of Lopinavir, Ritonavir, Saquinavir and NRTIs in HIV-1 Infected, Treatment-experienced, NNRTIresistant Subjects… Non-invasive assessment of atherosclerosis and its determinants in HIV-infected people IICT: Severe Hyperlactatemia and Lactic Acidosis in HIV-infected Patients Treated With Anti-retroviral Therapy: An International Case-control Study IICT: Study Evaluating the Frequency and Factors Associated with Osteoporosis in the HAART… Identification of sociodemographic risk factors associated with dev. of resistance Pilot, random. open-label study assessing safety, tolerability, efficacy… lopinavir/riton Grant in aid Analyze blood samples received from Abbott using UBC technology, PCR assay Study to compare long term safety, tolerability of stavudine extended released vs. Phase III parallel group study to compare GW873140 400 mg BID with ritonavir .. Prospective evaluation of changes in peripheral bloodmitochondrial DNA lactate Biojector Molecular Mechanism of Leishmania Pathogenesis (Salary) HIV and Hepatitis C Transmission Networks in a Cohort of Injection Drug Users in Vancouver's Downtown Eastside: How Structure and Context Matter BC Mass Immunization Clinic: Cold Chain Project The Immunologic, Genetic and Metabolic Basis for Abacavir Hypersensitivity Reaction: Further Application of Genetic, Immunologic and Cutaneous Testing Cutaneous and Genetic Testing for the Diagnosis of Abacavir Hypersensitivity Syndromes Economic evaluation of direct and non-medical costs associated…SARS
500,000.00 Functional Genomics of Emerging Infectious Diseases (PREPARE Project) 123,147.00 Monocyte Cell Regulation
224
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION Infectious Diseases Infectious Diseases Infectious Diseases Infectious Diseases
RESEARCHER Rekart Rekart Rekart Steiner
TYPE Grant Grant Grant Grant
Infectious Diseases Infectious Diseases
Steiner Steiner
Grant Grant
Infectious Diseases
Steiner
Grant
Infectious Diseases Infectious Diseases
Stiver Tyndall
Clinical Trial Grant
SPONSOR CIDA - BCCDC Vancouver Foundation - BCCDC Biolytical Laboratories CFI: Infrastructure Operating Fund 4453 CIHR: New Investigator Award (CIHR Scholarship) MSH 69156 VHHSC: Scholar Award CIHR: Operating Grant MOP-64355 in collaboration with The Institute of Infection and Immunity Various Pharmaceutical Companies AI411227... BC Centre for Excellence in HIV/AIDS
Infectious Diseases
Tyndall
Grant
Infectious Diseases
Tyndall
Grant
CIHR: Institute of Infection & Immunity Res. Prog. Dev. Grant HDD-77967 in collaboration with Centre for Excellence CIHR: HIV/AIDS Research Program CBR74917
2005 FUNDING $ 855,988.00 $ 48,885.00 $ 86,710.00 $ 835.00 $ $
$ $ $
$ $
Infectious Diseases
Wood
Grant
NIH (US): 2 R01 DA011591-04A1 in collaboration w/ the BCCDC, the University of California (San Diego), and the Canadian HIV/AIDS Legal Network $
Infectious Diseases Infectious Diseases Infectious Diseases Infectious Diseases
Wood Wood Wood Wood
Grant Grant Grant Grant
CIHR: Operating Grant HHP-67262 NIH Canadian Fdn for AIDS Research Health Canada
$ $ $ $
Nephrology Nephrology
Chiu Duncan
Clinical Trial Clinical Trial
AstraZeneca Canada Inc. Merck & Company, Inc.
$ $
Nephrology
Duncan
Clinical Trial
AstraZeneca Canada Inc.
$
Nephrology
Duncan
Clinical Trial
$
Nephrology
Gill
Grant
Ortho Biotech MSFHR - Scholar Award CI-SCH-041(041)HSR
Nephrology
Jastrzebski
Clinical Trial
Hoffmann-La Roche Ltd. (Canada)
$
Nephrology
Jung
Clinical Trial
Nephrology
Keown
Contract
Nephrology
Keown
Contract
UBC Department of Medicine
AstraZeneca UK Limited Novartis Pharma AG in collaboration with Genome British Columbia Novartis Pharma AG in collaboration with Genome British Columbia
$
$
TITLE STI/ HIV/ AIDS prevention and care in Southern Vietnam Evaluation of the impact of mandatory HIV reportability in B.C. Clinical protocol for point-of-care and lab investigational testing of Insti. HIV-1/HIV-2 CFI Infrastructure Operating Fund
58,500.00 Mechanisms of Innate Immune Signalling by Enteroaggregative E. coli Flagellin 50,000.00 Mechanisms of Innate Immune Signalling by Enteroaggregative E. coli Flagellin
96,648.00 Mechanisms of Innate Immune Signaling by Enteroaggregative Escherichia coli Flagellin The safety and efficacy of Cefepime versus Ceftriaxone in the treatment of non-hospital acquired pneumonia in the 34,689.00 elderly 125,157.00 Salary Support for Dr. Mark Tyndall
5,000.00 Enhancing uptake and sustainability of HIV care and antiretroviral therapy among survival sex workers 99,390.00 MAKA Initiative: HIV prevention and care among women survival sex workers
667,465.00 Evaluating the natural history of injection drug use The Vancouver injection drug user's study: A programme of study of HIVand Hepatitis C and other harms related to 158,355.00 injection drug use 115,100.00 HAART use, methamphetamine exposure, and HIV resistance among IVDU 60,000.00 Investigating barriers to HIV/AIDS care among injection drug users 500,000.00 Vancouver Supervised Injection Site Evaluation A double-blind, randomized, dose-ranging, multi-centre, phase III-b study to evaluate the efficacy and safety of high doses of candesartan cilexetil (Atacand) on the reduction of proteinuria in the treatment of subjects with hypertension 10,069.00 and… 15,824.00 SHARP: Study of Heart and Renal Protection 4522IL/0096 (AURORA) - Study to Evaluate the Use of Rosuvastatin in Subjects On Regular Haemodialysis: An Assessment of Survival & Cardiovascular Events: Double-blind, Randomized, Multicentre, Phase IIIb, Parallel-group 7,860.00 Study to Compare the .... Protocol EPO-IMU-401: An Active Safety Surveillance Plan to Prospectively Monitor the Incidence of Pure Red Cell 29,710.00 Aplasia (PRCA) in Patients Receiving Epoetin-Alfa Therapy 60,000.00 Access to Kidney Transplantation in B.C. and Alberta BA17283: Randomized, Controlled, Open-label, Multicentre, Parallel-group Study to Demonstrate the Efficacy & Safety of RO-0503821 when Administered Intravenously for the Maintenance Treatment of Anemia in Patients with 27,888.00 Chronic Kidney Disease... A study to evaluate the use of rosuvastatin in subjects on regular hemodialysis: An assessment of survival and cardiovascular events (AURORA)(4522IL-0096) - A double-blind, randndomised, multicentre, phase 3b parallel-group 6,554.00 study to compare...
$
647,173.00 CRA: Better Biomarkers Of Acute And Chronic Allograft Rejection
$
376,230.00 CRA: Better Biomarkers Of Acute And Chronic Allograft Rejection
225
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION
RESEARCHER
TYPE
Nephrology
Keown
Nephrology Nephrology
Keown Keown
Nephrology
Levin
Contract
SPONSOR Various Sources (VCHA, SPH Fdn, BC Transplant Society)
2005 FUNDING $
Clinical Trial Contract
Hoffmann-La Roche Ltd. (Canada) Genome British Columbia
$ $
Grant
MSFHR Postdoctoral Trainee Fellowship STPDF-345(04-1)CLIN (Fellow: Zalunardo, Nadia) $
$ $
TITLE
57,088.00 Better Biomarkers in Transplantation IICT: An Open Prospective, Randomized, Controlled, Multicentre Study Comparing Fixed Dose vs. Concentration552,299.00 controlled Mycophenolate Mofetil Regimens for de novo Patients Following Renal Transplantation 179,434.00 CRA: Better Biomarkers of Acute and Chronic Allograft Rejection
5,250.00 Renal function and cardiovascular outcomes in patients with artherosclerotic renal artery stenosis
Nephrology Nephrology
Levin Levin
Grant Grant
CIHR: Postdoctoral Fellowship MFE-63502 in collaboration w/ The Institute of Circulatory & Respiratory Health (CIHR) (Fellow: Khan, Nadia) Various Sources
Nephrology Nephrology Nephrology Nephrology
Levin Levin Levin Levin
Clinical Trial Grant Clinical Trial Grant
Hoffman-La Roche Canadian Institutes of Health Research Merck & Co., Inc. Shire Biochem Inc.
$ $ $ $
Nephrology
Levin
Clinical Trial
Genzyme Corporation
$
Nephrology
Levin
Grant
Kidney Foundation of Canada
$
Nephrology
Levin
Clinical Trial
$
Nephrology
Levin
Grant
Merck Frosst Canada Inc. Kidney Foundation: Biomedical Fellowship (Fellow: Zalunardo, Nadia)
$
Nephrology
Levin
Grant
Kidney Foundation of Canada
$
Nephrology Nephrology
Levin Macrae
Clinical Trial Grant
$ $
Nephrology Nephrology
Quamme Quamme
Grant Grant
Johnson & Johnson Kidney Foundation of Canada Kidney Foundation: Biomedical Research Grant CIHR: Operating Grant # MOP-53288
Nephrology
Shapiro
Clinical Trial
Astellas Pharma Canada, Inc.
$
Nephrology
Taylor
Clinical Trial
Baxter Healthcare Corporation, US
$
50,000.00 Characterization of MagT, a Novel Family of Renal Magnesium Transporters 166,250.00 Studies of Renal Magnesium Transport IICT: Does Fasting Plasma Glucose (FPG)/Oral Glucose Tolerance Testing (OGTT) Pre-transplant Predict Post20,000.00 transplant Diabetes Mellitus (PTDM) in Renal Transplantation? A Study to Evaluate the Efficacy and Safety of Extraneal Physiological pH Compared with Current Extraneal in 8,026.00 Patients Receiving Continuous Ambulatory Peritoneal Dialysis (CAPD) PRO-RENAL-REG-02A
$ $
64,872.00 The UBC Neuropsychology Laboratory for Investigation of Human Visual Processing and Ocular Motor Control 295,052.00 Perceptual encoding and imagery in prosopagnosia
Neurology Neurology
Barton Barton
Grant Grant
Neurology
Barton
Grant
Neurology
Barton
Grant
Neurology
Barton
Grant
UBC Department of Medicine
CFI: Canada Research Chairs Infrastructure Fund 202111 NIH (US): Research Grant MSFHR: Establishment Grant CI-SSH035(03-1)CLIN MSFHR: Senior Scholar Award CI-SSH035(03-1)CLIN MSFHR: Matching Establishment Grant CISSH-035(03-1)
$ $
The value of cardiac specific troponin in predicting cardiac outcomes in an asymptomatic chronic kidney disease 8,334.00 population 35,973.00 NERC An Open-label, Randomized, Multicentre, Parallel-group Study to Demonstrate Correction of Anemia Using 26,944.00 Subcutaneous Injections of RO0503821 in Patients With Chronic Kidney Disease Who Are Not On Dialysis 96,757.00 Canadian Prevention of Renal and Vascular Endpoints Trial 629,236.00 Study of Heart and Renal Protection (SHARP) 175.00 A retrospective chart review to document the control of mineral metabolism in dialysis-dependent patients An International, Non-invasive Study to Determine the Prevalence of Vascular Calcification in Chronic Kidney Disease 20,225.00 Subjects on Hemodialysis Atherosclerosis/ Cytokine: Longitudinal study of atherosclerosis in renal disease and renal insufficiency, and comorbid 17,532.00 conditions: Focus of left ventricular hypertrophy and cardiac disease in patients with progressive renal disease A Randomized Control Trial Comparing Combined Cardiology, Kidney and Diabetic Care Clinic (CCKDC) to Current 175,000.00 Therapy Received In Multiple Clinics: Improving Care and Resource Utilization 22,500.00 Renal function and cardiovascular outcomes in patients with atherosclerotic renal artery stenosis Care prior to dialysis: A multicentre prospective cohort study in renal insufficiency to assess the impact of elements of 13,196.00 care on patient outcomes (CREDA) An Active Safety Surveillance Plan to Prospectively Monitor the Incidence of Pure Red Cell Aplasia (PRCA) in Patients 59,079.00 Receiving Epoetin Alfa Therapy 22,500.00 Biomedical Fellowship
$
74,046.00 Neuropsychology of vision and eye movements
$
15,000.00 Neuropsychology of vision and eye movements
$
37,500.00 Neuropsychology of vision and eye movements
226
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION
RESEARCHER
TYPE
SPONSOR MSFHR: Junior Graduate Studentship Award ST-JGS-028(04-1)CLIN Dept of Med. Academic Enhancement Fund: Academic Scholar Program VCHA - Academic Enhancement Fund: Academic Scholar Program Canada Research Chair Tier II (CIHR) 950202111 CIHR Operating Grant MOP-77615 Canada Research Chair Tier 1(CIHR) BC Ministry of Advanced Education, Training & Technology
2005 FUNDING
Neurology
Barton
Grant
Neurology
Barton
Grant
Neurology
Barton
Grant
Neurology Neurology Neurology
Barton Barton Cashman
Grant Grant Grant
Neurology
Cashman
Agreement
Neurology
Cashman
Grant
Neurology
Cashman
Grant
$ NCE: National Centers of Excellence in collaboration with Vancouver Coastal Health Research Institute $ CFI: Canada Research Chairs Infrastructure Fund 202092 $
Neurology
Chapman
Clinical Trial
Takeda Global Research and Development
$
Neurology
Chapman
Clinical Trial
Takeda Global Research and Development
$
Neurology Neurology
Devonshire Doudet
Clinical Trial Contract
Biogen Idec, Inc. C-1808 Schering Ag
$ $
(01-04-TL-128-003) Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the 98,610.00 Efficacy and Safety of Three Doses of TAK-128 in Subjects with Mild to Moderate Diabetic Peripheral Neuropathy (01-05-TL-128-006) An Open-label, Multi-centre Study to Evaluate the Safety of Long-term Administration of TAK28 in 3,435.00 Subjects with Mild to Moderate Diabetic Peripheral Neuropathy (C-1808:) An Open-label Multicenter Extension Study to Evaluate the Safety and Tolerability of Natalizumab in 42,861.00 Subjects with Multiple Sclerosis who have Completed Studies C-1801, C-1802 or C-1803 94,500.00 Evaluation of three preparations of Spheramine in a rodent model of Parkinson's disease
$ $
The effects of electroconvulsive therapy in an animal model of Parkinson's disease: Mechanisms of a potential adjunct 1,041.00 treatment 17,277.00 Effects of striatal implantation of RPE cells in a rodent model of Parkinson's Disease
$
16,900.00 Interactive case-based approach to neuro-ophthalmologic education on the internet
$
16,900.00 Interactive case-based approach to neuro-ophthalmologic education on the internet
$ $
Neurology Neurology
Doudet Doudet
Grant Agreement
Neurology
Doudet
Grant
VCHRI: Interdisciplinary Grant
$
Neurology Neurology
Doudet Doudet
Grant Grant
$ $
Neurology
Eisen
Clinical Trial
Titan Pharmaceuticals Inc. CIHR: Operating Grant MOP-74746 Aventis Pharma Inc. RP54274/CA1.401
$ $
Neurology
Feldman
Clinical Trial
Neurology
Feldman
Clinical Trial
GlaxoSmithKline Inc. COL40328
Neurology
Feldman
Clinical Trial
Neurology
Feldman
Clinical Trial
Neurology
Feldman
Grant
Neurology
Feldman
Grant
UBC Department of Medicine
2,292.00 The effects of stress on synaptic plasticity: Mechanistic application for psychiatric disorders
$
MSFHR: Senior Graduate Studentship Award ST-SGS 128(03-1)BM (Fellow: Strome, Elissa) Titan Pharmaceuticals Inc.
National Inst. Of Health 53-00-ADNI, CFDA #93.866 in collaboration with The University of California (San Diego)
TITLE
$
100,000.00 Canada Research Chair for Dr. Jason Barton in Neuropsychology - Vision and Eye Movements $50,656.00 Processing of face recognition in patients with occipitotemporal lesions after posterior cerebral infraction 216,667.00 Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases for Dr. Neil Cashman 50,000.00 UBC NCE Provincial Infrastructure: PrioNet Canada
100,000.00 PrioNet Canada - Full Application Preparation (FAP) 99,752.00 Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases
10,000.00 MRI labeling for human retinal pigment epithelial cells: In vitro development of a potential method for in vivo follow-up Stereological assessment of the survival of human retinal pigmented epithelial cells implanted in a rodent model of 20,427.00 Parkinson's disease 54,453.00 Effect of electroconvulsive therapy on an animal model of Parkinson's disease A Canadian Multicentre Phase IV Comparative Study of the Effect of Riluzole 50 mg bid on the Survival of ALS 64,524.00 Subjects Compared to Historical Controls - The CARE STUDY
4,262.00 IICT (Government): Alzheimer Disease Neuroimaging Initiative (ADNI) Multi-site Collaborative Study for Genotype-Phenotype Associations in Alzheimer's Disease: the GenAda Study 14,700.00 Protocol ALDHD2001/00013/00
Pfizer Canada Inc. A2581078 ONO Pharma USA, Inc. CTA-ONO2506POU010 w/PharmaNet, LLC
$
25,773.00
$
55,159.00
Various Pharmaceutical Companies CIHR: Institute of Aging Pilot Project Grant IAP-73376
$
175,000.00
$
50,000.00
227
The LEADe Study: 80-week Randomized, Multicenter, Parallel-group, Double-blind Study of the Efficacy and Safety of Atorvastatin 80mg + Acetylcholinesterase Inhibitor vs. an Acetylcholinesterase Inhibitor Alone in the Treatment of Mild … (ONO-2506POU010) Double-blind Phase II Safety and Efficacy Evaluation of ONO-2506PO in Patients with Mild to Moderate Alzheimer's Disease ACCORD II - A longer term Assessment of cognitive Impairment and Dementia Syndromes with an Evaluation of Treatment Effectiveness Preventing Alzheimer disease and other dementias: The development of a statistical framework for the design of randomized controlled trials
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION
RESEARCHER
TYPE
SPONSOR
Neurology
Feldman
Grant
CIHR: Operating Grant MOP-74580 in collaboration w/ The University of Toronto
$
Neurology
Feldman
Clinical Trial
Sanofi-Synthelabo Canada Inc.
$
Neurology Neurology
Feldman Feldman
Clinical Trial Grant
Sanofi-Synthelabo Canada Inc. Janssen-Ortho Inc
$ $
Neurology
Gibson
Clinical Trial
Eli Lilly Canada Inc.
$
Neurology
Gibson
Clinical Trial
Eli Lilly Canada Inc.
$
Neurology
Gibson
Clinical Trial
Bayer Corp.
$
Neurology Neurology
Hashimoto Hsiung
Clinical Trial Grant
Biogen Idec, Inc. Department of Medicine
$ $
Neurology
Johnston
Clinical Trial
Sanofi-Synthelabo Canada Inc.
$
Neurology
Jones
Clinical Trial
Warner-Lambert Canada Inc.
$
Neurology
Jones
Clinical Trial
Pfizer Canada Inc.
$
Neurology
Jones
Clinical Trial
$
Neurology Neurology Neurology
Kastrukoff Kastrukoff Kastrukoff
Contract Grant Grant
UCB Pharma, Inc. Globe Laboratories Inc. (with Chemokine Therapeutics Corp.) Chemokine Therapeutics Corp CIHR: Operating Grant MOP-74495 Novartis Pharmaceuticals Canada Inc., CTCH346A 2211E1
Neurology
Krieger
Clinical Trial
Neurology
Lee
Clinical Trial
Neurology
Lee
Grant
Neurology Neurology Neurology Neurology Neurology
Lee Lee Li Li Li
Grant Grant Contract Contract Grant
Eisai Co. Ltd. in collaboration with Pharmaceutical Research Associates, Inc. MSFHR: Senior Scholar Award CI-SSH038(03-1)BIOM MSFHR: Establishment Grant CI-SSH038(03-1)BIOM CIHR: Operating Grant MOP 69382 Aventis Pharma Various Sources Donations
Neurology Neurology Neurology
Martzke McKeown McKeown
Grant Agreement Grant
CIHR: Operating Grant MOP-62966 National Parkinson Foundation (US) VCHRI: Interdisciplinary Grant
UBC Department of Medicine
2005 FUNDING
TITLE
235,505.00 Frontotemporal dementia with ubiquinated inclusions: clinical, genetic and pathological characterization LTS5283: Long-term Safety Extension of Phase II Study EFC5286 of SR57667B in Patients with Mild to Moderate 2,800.00 Alzheimer's Disease Protocol EFC5286: Phase II Multicentre, Multinational, Randomized, Double-blind, Placebo-controlled, Efficacy, Safety 30,875.00 and Tolerability Study of SR57667B in Patients with Mild to Moderate Alzheimer's Disease 46,930.00 Data management for HOPE.BD 3,468.00 Protocol B7A-MC-MBCW: LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes Protocol B7A-MC-MBBR: LY333531 Treatment of Peripheral Neuropathy in Patients with Diabetes: A Phase III Pivotal 6,886.00 Clinical Trial Protocol 100538: Multicentre, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C) 10% Treatment in Subjects with Chronic Inflammatory Demyelinating 13,391.00 Polyneuropathy C-850 CHAMPIONS: Controlled High Risk AVONEX Multiple Sclerosis Prevention Study in Ongoing Neurological 10,022.00 Surveillance 25,000.00 Vascular risk and genetics of Alzheimer's disease and related dementias
$ $ $
10,266.00 Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Pregabalin add-on trial: A double-blind, placebo-controlled, multicentre study in patients with partial seizures (100816,417.00 009) Protocol 1008-164: Pregabalin BID Open-label, Add-on Trial: A Follow-on Study to Determine Long-term Safety and 2,756.00 Efficacy in Patients with Partial Seizures N167: Open-label, Multicentre, Follow-up Study to Evaluate the Safety and Efficacy of Levetiracetam (LEV) (oral tablets of 166, 250 or 500 mg bid) at Individualized Doses up to a Maximum of 4000 mg/day (or 80mg/kg/day for 3,009.00 children and adolescents) Determination of Peripheral Blood Mobilization of Committed Progenitors or Colony Forming Cells Following 27,532.00 Administration of Compounds in Female Balb/c Mice 11,471.00 The immune response in Multiple Sclerosis 98,400.00 Natural killer (NK) and natural killer T (NKT) cells in Herpes Simplex Virus Type 1 (HSV 1) infections in mice
$
CTCH346A 2211E1: Long-term Extension to a Randomized Double-blind, Placebo-controlled, Stratified, Parallelgroup, Multicenter, Dose-ranging Study Evaluating Four Oral Doses of TCH346(1.0,2.5,7.5 and 15mg) Administered 7,839.00 Once Daily in Patients…
$
E2020-E044-316: A 24-week Multicentre, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, 7,476.00 Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients with Dementia
$
100,000.00 Studies on Rational Treatment of Parkinson's Disease
$ $ $ $ $
37,500.00 116,457.00 700,000.00 300,000.00 51,500.00
$ $ $
Studies on Rational Treatment of Parkinson's Disease Neural Mechanisms Underlying Response Changes to Levidopa in Parkinson's Disease MS/MRI operating - research group MS/MRI operating funds - admin office Health Science Research Donations
12,079.00 Neurobehavioural Outcome Following Implantation of Bilateral Subthalmic Nucleus Stimulators in Parkinson's Disease 53,794.00 (01 Account) Designation as a National Parkinson Foundation - Centre of Excellence 10,000.00 Novel Assessment of Motor Performance in Patient Populations
228
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION
RESEARCHER
TYPE
SPONSOR
2005 FUNDING
Neurology
Oger
Clinical Trial
Acorda Therapeutics, Inc. MS-F203
$
Neurology
Oger
Clinical Trial
Biogen Idec, Inc. C-1801
$
Neurology
Oger
Clinical Trial
Berlex Canada Inc. 304747
$
Neurology
Oger
Clinical Trial
Biogen Idec, Inc. C-867
$
Neurology
Oger
Clinical Trial
Neurocrine Biosciences Ltd. NBI-5788-0201 $
Neurology
Oger
Clinical Trial
Aventis Pharma Inc. HMR 1726/2002
$
Neurology
Oger
Clinical Trial
Berlex Canada Inc
$
Neurology
Oger
Clinical Trial
Genentech, Inc.
$
Neurology
Oger
Clinical Trial
Bayhill Therapeutics, Inc
$
Neurology
Oger
Clinical Trial
Abbott Laboratories, Limited (Canada) M03654 $
Neurology
Oger
Clinical Trial
Berlex Canada Inc. #308272
$
TITLE (MS-F203) Double-blind, Placebo-controlled, 21-week Parallel-group Study to Evaluate Safety and Efficacy of Oral 9,901.00 Fampridine-SR (10mg BID) in Subjects with Multiple Sclerosis C-1801: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Determine the Safety 20,127.00 and Efficacy of Natalizumab in Subjects with Relapsing-Remitting Multiple Sclerosis (304747:) Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability and Efficacy of 8 MIU Interferon Beta-1b (Betaseron) in Patients with a First Demyelinating Event 6,715.00 Suggestive of MS
Protocol C-867: Multicentre, Open-label, Immunogenicity and Safety Study of a Serum-Free Pre-Formulated Solution 12,153.00 of Avonex (Interferon beta 1a) Administered Intramuscularly to Patients with Relapsing/Remitting Multiple Sclerosis Protocol NBI-5788-0201: Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety, Tolerability and 6,707.00 Efficacy of NBI-5788 in Patients with Relapsing-Remitting Multiple Sclerosis Protocol HMR 1726D/2002: Extension of Protocol HRM 1726D/2002, A Phase II Study of the Safety & Efficacy of 32,741.00 Teriflunomide (HMR 1726) in Multiple Sclerosis with Relapses 306440 BEYOND Study: International, Randomized, Multicenter, Phase 3b Study in Patients with Relapsing-Remitting Multiple Sclerosis Comparing Over a Treatment Period of 104 Weeks: Double-blinded, Safety, Tolerability and Efficacy 112,295.00 of Betaseron/B… (U2786g) Phase II/III Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Safety and 123,021.00 Efficacy of Rituximab in Adults with Primary Progressive Multiple Sclerosis (PPMS) BHT-3009-01: Phase l Trial of Immunotherapy with BHT-3009 Alone or Combined with Atorvastation in Patients with 54,462.00 Multiple Sclerosis M03-654: A 24-week Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-finding, Safety, Tolerability & Efficacy Study of the Human Anti-IL-12 Antibody ABT-874 in Subjects with Multiple Sclerosis with a 24-week Double24,546.00 blind Active… (308272) A Long-term Follow-up of Patients Enrolled in the Pivotal Study of Betaserone (interferon beta 1b) in 105,833.00 Relapsing, Remitting Multiple Sclerosis
Neurology
Oger
Clinical Trial
Aventis Pharma Inc. HMR1726D/3001
$
Neurology
Oger
Clinical Trial
Novartis Pharmaceuticals Canada Inc. CFTY720D2201 E1
$
HMR1726D/3001: Randomized, Double-blind, Placebo-controlled, Parallel-group Design Study to Evaluate the Efficacy and Safety of Teriflunomide (HMR 1726D) in Reducing the Frequency of Relapses and Delaying the 26,124.00 Accumulation of Physical Disabilities… (CFTY720D2201E1: extended to CFTY720D2201) Extension of the Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicentre Study Evaluating Safety, Tolerability and Effect on MRI Lesion Parameters of FTY720 vs. 48,932.00 Placebo in Patients with Relapsing…
$
(MPB8298-01) Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy and Safety of MBP8298 in 230,632.00 Subjects with Secondary Progressive Multiple Sclerosis
$
Neurology
Oger
Clinical Trial
BioMS Technology Corp. MBP8298-01 in collaboration with Endpoint Research Ltd.
Neurology
Oger
Clinical Trial
Merck Frosst Canada Inc. No. 003-00
Neurology
Oger
Clinical Trial
Neurology
Oger
Grant
Neurology Neurology Neurology
Oger Oger Oger
Contract Grant Grant
Transition Therapeutics and Diagnostics Inc. MSSC: Career Development Award (Fellow: Tremlett, Helen) National Institutes of Health (NO1-AI-15416 AGMT#3217SC) in collaboration with The Immune Network Research Ltd. Donations for Health Science Research Donations
Neurology
Oger
Agreement
Berlex Canada Inc.
UBC Department of Medicine
(003-00) A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effects of L7,550.00 000124467 on Disease Activity in Patients with Relapsing, Remitting Multiple Sclerosis as Measured by MRI
$
(IET-201) Open-label, Baseline-to-Treatment Crossover Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Effects of Vitamin B12 When Used in Combination with Interferon-b Treatment in Patients with 29,791.00 Relapsing, Remitting Multiple Sclerosis
$
50,000.00 The Impact of Beta-interferon Therapy on Multiple Sclerosis: Effectiveness and Toxicity
$ $ $
Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Efficacy of NBI-5788 in 21,601.00 Patients with Relapsing-remitting Multiple Sclerosis (NBI-5788-0201) 2,100.00 Myasthenia Gravis Research 3,178.00 Neuro-Immunology Research
$
60,000.00 Setting Up the MxA Bioavailability Assay for Multiple Sclerosis Patients Treated with Interferons
229
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION
RESEARCHER
TYPE
SPONSOR Myasthenia Gravis Fdn: Henry R. Viets Research Fellowship (Fellow: Eom, Gina) CIHR: Operating Grant MOP 38062 CFI: Infrastructure Operating Fund 5034 CFI: Infrastructure Operating Fund 5034 CIHR: Operating Grant MOP - 67007
Neurology Neurology Neurology Neurology Neurology
Oger Pelech Ruth Ruth Ruth
Grant Grant Grant Grant Grant
Neurology
Sossi
Grant
Neurology
Spacey
Neurology
Stoessl
2005 FUNDING $ $ $ $ $ $
Grant
CIHR: Operating Grant MOP-74638 MSFHR: Institutional Infrastructure Support Program
Clinical Trial
Boehringer Ingelheim (Canada) Ltd.
$
$
TITLE
Investigating Seronegatvie Myastenia Gravis - A Chart Review for Quality Assurance Protein Kinase Pathways in Seastar Oocyte Cell Cycle Control CFI Infrastructure Operating Funds: Functional Imaging in Basic Biomedical Research Operations CFI Infrastructure Operating Funds: Functional Imaging in Basic Biomedical Research - Centre Share Development of Radiotracers Based on Oligonculeotides Labeling In-vivo studies on disease and treatment induced changes of levodopa-derived dopamine kinetics and DA transporter 135,095.00 expression using a Parkinson's disease rat model and a microPET In it for Life: Mentored Clinician Scientist Salary - Paroxysmal neurological disease: the role of the human P/Q type 50,000.00 calcium channel (SCEPTRE - 1198.100:) A Fourteen-week, Placebo-controlled, Dose-response Efficacy & Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake 13,161.00 Inhibitor)
3,447.00 107,531.00 46,360.00 5,000.00 94,086.00
Neurology
Stoessl
Clinical Trial
Sanofi-Synthelabo Canada Inc.
$
Neurology
Stoessl
Clinical Trial
Kyowa Pharmaceutical, Inc. in collaboration with Lineberry Research Associates
$
Protocol ACT5288: Phase II Randomized, Multicentre, Multinational, Double-blind, Placebo-controlled Study of the Effect of SR57667B on Dopaminergic Nigro-striatal Function Assessed by 18F-Dopa PET Imaging in Outpatients with 165,575.00 Early Parkinson's Disease 8.5 A 12-week, Double-blind, Placebo-controlled, Randomized, Multicenter Study of the Efficacy of 40mg/day KW6002 as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa/Carbidopa 138,936.00 Therapy
Clinical Trial Contract
Kyowa Pharmaceutical, Inc. 6002-INT-001 in collaboration with Lineberry Research Associates US National Parkinson Fdn: Research
$ $
6002-INT-001: Long-term, Multicenter, Open-label Study with Oral 20 or 40 mg/doses of KW-6002 (Istradefylline) as 57,041.00 Treatment for Parkinson's Disease in Patients with Motor Response Complication on Levodopa Therapy 152,095.00 National Parkinson Foundation, Centre of Excellence
Grant Grant Grant
MSFHR: Junior Graduate Studentship Award ST-JGS-055(04-1) CLIN - Lidstone, Sarah Various sources 16-017292-7 CIHR: Operating Grant MOP-15127
$ $ $
1,458.00 The Roles of Expectation and Dopamine in the Placebo Effect in Parkinson's Disease 100,977.00 Movement Disorder Clinic 191,115.00 The natural history of sporadic and inherited Parkinson's disease
$ $ $
127,761.00 Studies on Fluctuations in Response to Dopaminergic Therapy 200,000.00 Canada Research Chair - A. Jon Stoessl 168,123.00 Expectation, the Placebo Effect and Dopamine Release in Parkinson's Disease
Neurology Neurology
Neurology Neurology Neurology
Stoessl Stoessl
Stoessl Stoessl Stoessl
Neurology Neurology Neurology
Stoessl Stoessl Stoessl
Grant Grant Grant
Neurology
Stoessl
Grant
MRC: Operating Grant MT-15126 in collaboration with The University of Wisconsin-Madison Canada Research Chair Tier I (CIHR) CIHR: Operating Grant MOP-74579 CIHR: Team Grant CTL-77114 in collaboration with Mayo Clinic ( )
$
$
Neurology
Teal
Clinical Trial
CDA#93.853 in collaboration with the University of Medicine & Dentistry of New Jersey
Neurology Neurology
Teal Teal
Clinical Trial Clinical Trial
Pfizer Canada Inc. Canadian Institutes of Health Research
$ $
Neurology
Teal
Clinical Trial
Boehringer Ingelheim (Canada) Ltd.
$
Neurology
Teal
Clinical Trial
AstraZeneca Canada Inc.
$
Neurology
Teal
Clinical Trial
AstraZeneca Canada Inc.
$
Neurology
Teal
Clinical Trial
Sanofi-Synthelabo Canada Inc.
$
UBC Department of Medicine
10,000.00 LOI: Monoaminergic Function of the Brain in Health and Disease
8,179.00 IICT: CREST - Carotid Revascularization Endarterectomy vs. Stenting Trial A double-blind, randomized, placebo-controlled study of Atorvastatin as prevention of Cerebrovascular events in 106,286.00 patients with a previous transient Ischemic Attack (TIA) or stroke 7,650.00 FASTER: Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence Trial 9.159 PROFESS: Prevention Regimen for Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo63,335.00 controlled Study of Aggrenox vs. Clopidogrel and Aspirin with and without Micardis Protocol SA-NXY-0007: Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicentre, Phase IIb/III 123,420.00 Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke SA-NXY-0012 CHANT: Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Phase IIb Study to Assess the Safety and Tolerability of 72 Hours Intravenous Infusion on NXY-059 in Adult Patients With Acute 27,000.00 Intracerebral Hemorrhage Protocol EFC4505: (CHARISMA) Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management 46,829.00 and Avoidance
230
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION
RESEARCHER
TYPE
SPONSOR
2005 FUNDING
TITLE
2506/INT0104: A Randomized, Double-blind, Placebo-controlled, Multicentre Study of the Effects of ONO-2506 IV Infusion on the Amelioration of Neurological Damage and Improvement of Stroke Assessment Scale Scores in 13,270.00 Patients with Acute Ischemic Stroke Protocol CO116T41 AbESTT-II: Abciximab (ReoPro) in Acute Ischemic Stroke: A Phase III Multinational, Multicentre, 23,154.00 Randomized, Double-blind, Placebo-controlled Trial Protocol GA 9014: Multicentered, Randomized, Double-blind, Placebo-controlled, Parallel Study Assessing the Add-on Effect of Minocycline in Relapsing-Remitting Multiple Sclerosis (RR-MS) Subjects Treated with Glatiramer Acetate 83,687.00 (GA) 38,200.00 The impact of beta-interferon therapy on MS: Effectiveness and toxicity An Open Label Safety and Immunogenecity Study of MYOBLOC (Neurobloc; Botulinim Toxin Type B) Injectable 20,278.00 Solution in Patients with Cervical Dystonia
Neurology
Teal
Clinical Trial
ONO Pharma USA, Inc.
$
Neurology
Teal
Clinical Trial
Eli Lilly Canada Inc.
$
Neurology Neurology
Traboulsee Tremlett
Clinical Trial Grant
Teva Neuroscience, GP MSSC: Research Grant
$ $
Neurology
Tsui
Clinical Trial
$
Neurology Neurology Neurology Neurology Neurology Neurology Neurology Neurology
Wang Wang Wang Wang Wang Wang Wang Wang
Grant Grant (BRC) Grant (BRC) Grant (BRC) Grant (BRC) Grant (BRC) Grant (BRC) Grant (BRC)
Solstice Neuroscience, Inc. AN072-401CD NCE/Canadian Stroke Network Studentship (Lai, Ted) Howard Hughes Medical Institute CIHR Investigator Award MSFHR (Fellow: Wong, Tak Pan) CIHR CIHR Heart and Stroke Fdn of BC CIHR (Fellow: Wong, Tak Pan)
$ $ $ $ $ $ $ $
5,000.00 108,000.00 81,900.00 7,000.00 143,065.00 171,021.00 112,681.00 40,000.00
Neurology Neurology Neurology
Wang Wang Wang
Grant (BRC) Grant (BRC) Grant (BRC)
$ $ $
45,000.00 Pre-clinical studies on treatment of stroke with inhibitors of NMDA-receptor PSD95 interaction 55,312.00 Postsynaptic regulation of neurotransmission 500,000.00 Synaptic repair by peptides interfering with protein-protein interactions
Neurology Neurology Neurology Neurology Neurology Neurology Neurology Neurology Neurology
Wang Wang Wang Wang Wang Wang Wang Wang Wang
Grant (BRC) Grant (BRC) Grant (BRC) Grant (BRC) Grant (BRC) Grant (BRC) Grant (BRC) Grant (BRC) Grant (BRC)
$ $ $ $ $ $ $ $ $
22,500.00 80,713.00 7,000.00 40,000.00 5,000.00 20,000.00 2,500.00 150,000.00 22,154.00
Neurology
Wang
Grant (BRC)
Canadian Stroke Network MSFHR Neuroscience Canada Fragile X Foundation (Fellow: Chery, Nadege) High Q Foundation MSFHR (Fellow: Howland, John) CIHR (Fellow: Howland, John) CIHR (Fellow: Howland, John) CIHR (Fellow: Chery, Nadege) CIHR (Fellow: Chery, Nadege) CIHR CIHR Heart and Stroke Fdn of BC (Fellow: Gaertner, Tara)
Neurology Neurology Neurology
Wang Wang Woolfenden
Grant (BRC) Grant (BRC) Clinical Trial
Neurology
Woolfenden
Physical Medicine & Rehabilitation Physical Medicine & Rehabilitation Physical Medicine & Rehabilitation Physical Medicine & Rehabilitation
CSN Summer Studentship - The Dual Role of Uric Acid in Stroke Protein-protein interaction mediates co-trafficking of G protein-coupled receptors Postsynaptic regulation of neurotransmission Modulation of ligand-gated receptors by G protein-coupled receptors AMPA receptor regulation and synaptic plasticity Regulation of post-synaptic expression of GABA-A-receptors Depression of AMPA receptor-mediated excitation by insulin Modulation of ligand-gated receptors by G protein-coupled receptors
The role of mgluR activation in AMPAR trafficking Treat-HD A sub-unit specific role for NMDA receptor antagonism in neonatal seizures Animal modelling schizophrenia Animal modelling schizophrenia The role of mgluR activation in AMPAR trafficking The role of group 1 mgluR activation in AMPAR trafficking LTD blocking peptides as a therapy for neuropsychiatric illnesses and stroke The Synapse
$
41,500.00 Glutamate receptor insertion during synaptic plasticity: Real-time visualization and molecular mechanisms
MSFHR (Fellow: Taghibiglou, Changiz) CIHR (Fellow: Taghibiglou, Changiz) Novo-Nordisk
$ $ $
Clinical Trial
University of Cincinnati
$
7,500.00 Role of lipid rafts in AMPA receptor trafficking and synaptic plasticity 45,000.00 Role of lipid rafts in AMPA receptor trafficking and synaptic plasticity 8,554.00 F7ICH-1641: Factor VII (Niastase) in Acute Intracerebral Hemorrhage IICT: Protocol A2412 Interventional Management of Stroke (IMS) with EKOS Small Vessel Ultrasound Infusion 59,418.00 System
Anton
Grant
Rick Hansen Man In Motion Foundation
$
Dhawan
Clinical Trial
Allergan Inc.
$
21,000.00 Assessing fatigue in persons with spinal cord injury Protocol 191622-056: Multicenter, Open-label Study of the Safety of Repeated Doses of Botox (Botulinum Toxin Type 5,284.00 A) Purified Neurotoxin Complex for the Treatment of Focal Upper Limb Poststroke Spasticity
Hughes
Grant
$
30,000.00 Characterization of rehabilitation therapies and their association with specific outcomes in spinal cord injury
Townson
Grant
Rick Hansen Man In Motion Foundation UBC Faculty of Medicine: Summer Studentship Research (Fok, Mark)
UBC Department of Medicine
$
4,800.00 Measuring Fatigue in Medical Trainees
231
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION Physical Medicine & Rehabilitation Physical Medicine & Rehabilitation Physical Medicine & Rehabilitation
RESEARCHER
TYPE
SPONSOR
van Rijn
Grant
van Rijn
Grant
Vancouver Coastal Health Authority $ MSFHR: Networking Infrastructure Program IN NTG 107 045 $
Weeks
Grant
Rick Hansen Man In Motion Foundation
$
Respiratory Respiratory
Abboud Abboud
Grant Grant
WCB - Operating Project Grants Donations for Health Science Research
$ $
Respiratory
Abboud
Agreement
WCB - RS2003/04-022
$
Respiratory
Abboud
Grant
BC Lung Association
$
Respiratory Respiratory
Ayas Ayas
Clinical Trial Grant
$ $
Respiratory
Ayas
Grant
Respiratory
Ayas
Grant
Respiratory
Ayas
Grant
Respiratory Respiratory Respiratory Respiratory
Ayas Ayas Ayas Bai
Grant Grant Grant Grant
Respironics Inc. BC Lung: Project Grant CIHR: New Investigator Award (CIHR Scholarship) JBH-56261 MSFHR: Establishment Grant CI-SCH060(03-1) HSR MSFHR: Scholar Award CI-SCH-060(031)HSR MSFHR: Matching Establishment Grant CISCH0-060(03-1) BC Lung/CIHR Investigator BC Lung Association CIHR: Operating Grant MOP-42537
Respiratory
Cook
Grant
Respiratory
Cook
Grant
Respiratory
Duronio
Contract
Respiratory
Duronio
Grant
Respiratory
Duronio
Grant
Respiratory Respiratory Respiratory Respiratory
Duronio Duronio Duronio Duronio
Grant Grant Grant Grant
Respiratory
Fera
Clinical Trial
Respiratory
Fitzgerald
Grant
UBC Department of Medicine
MSFHR: Institutional Infrastructure Support Program Department of Medicine Academic Enhancement Fund Forbes Medi-Tech Inc. MSFHR: Senior Scholar Award Cl-SSH70(01-1) MSFHR: Senior Graduate Studentship Award ST-SGS 125(03-1)BM (Fellow: Scott, Alexander) MSFHR: Postdoctoral Trainee Fellowship ST-PDF 164(03-1)BM (Fellow: Germain, Marc) CIHR Operating Grant CIHR:Operating Grant MOP-74481 H&SFBC: Research
Altana Pharma, Inc. MSFHR: HSPR Operating Grant - Full Application
2005 FUNDING
$ $
TITLE
44,000.00 Salary: Research Nurse 300,000.00 Disabilities Health Research Network International Version of the Spinal Cord Independence Measure (SCIM): A Multicenter Evaluation of Reliability and 6,820.00 Validity Evaluation of Electronically Recorded Occupational Peak Flow Monitoring and Weekly Occupational Change in 18,092.00 Spirometry as Substitutes for Inhalation Challenge Testing in Red Cedar Asthma 500.00 Donations Evaluation of Electronically Recorded Occupational Peak Flow Monitoring and Weekly Occupational Change in 17,720.00 Spirometry as Substitutes for Inhalation Challenge Testing in Red Cedar Asthma Evaluation of proteases, antiproteases and inflammatory mediators in pulmonary alveolar macrophages in volunteers, 22,500.00 in relation to emphysema IICT: REMStar Auto with C-Flex: In Laboratory Performance vs Conventionally Titrated CPAP Therapy: Performances 19,163.00 and Preferences 21,600.00 Public Health & OSAH: Work Productivity, Occupational Injuries and MVC 25,000.00 Investigation of the diagnosis and treatment of sleep disordered breathing MSFHR/WCB scholar award: The public health impact of obstructive sleep apnea hypopnea. A focus on work 37,500.00 productivity, occupational injuries and motor vehicle crashes.
$ $ $ $
45,000.00 The public health impact of obstructive sleep apnea hypopnea The public health impact of obstructive sleep apnea hypopnea: a focus on work productivity, occupation injuries and 12,500.00 motor vehicle crashes 25,000.00 Investigation of the diagnosis and treatment of sleep disordered breathing 20,000.00 The Public Health and Safety Impact of Obstructive Sleep Apnea 40,651.00 Modulation of airway function by neurotrophic cytokines
$
In it for Life Mentored Clinician Scientist Award: Using location-based screening to improve tuberculosis control efforts 60,000.00 in high-risk communities of the Vancouver Coastal Health Authority
$
$ $ $
$
$ $ $ $
40,000.00 Salary Award Effects of Forbes Compounds on oxLDL Transport, Signalling Pathways in oxLDL-responsive Macrophages, and 12,188.00 Foam Cell Formation/Reversion 100,000.00 Key Signalling Pathways Controlling Survival and Death of Hemopoietic Cells
2,500.00 The roles of apoptosis and IGF-1 in tendinosis of the rotator cuff
39,000.00 59,677.00 141,673.00 68,421.00
Analysis of nuclear and cytoplasmic Mcl-1 protein complexes Cytokine regulated signalling pathways in inflammatory cells Mcl-1 as a regulator of cell cycle progression Activation of Macrophage Growth and Survival Pathways by Oxidized LDL
$
BY217 M2-121 The HERO Study: A 24-week, double-blind, randomised study to investigate the effect of 500ug roflumilast tablets once daily vs. placebo on parameters indicative of hyperinflation in patients with chronic obstructive 45,172.00 pulmonary…
$
50,000.00 Health Care Costs Related to Asthma in British Columbia
232
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION
RESEARCHER
TYPE Grant
SPONSOR CIHR/ICRH: New Frontiers Program NFD74311
Respiratory
Fitzgerald
Respiratory
$
Fitzgerald
Clinical Trial
AstraZeneca Canada Inc. D5890L00004
$
Respiratory
Fitzgerald
Clinical Trial
$
Respiratory
Fitzgerald
Clinical Trial
Merck Frosst Canada Ltd. GlaxoSmithKline Inc. in collaboration w/ Providence Health Care
Respiratory
Fitzgerald
Clinical Trial
Boehringer Ingelheim (Canada) Ltd. BI 205.301
Respiratory Respiratory
Fitzgerald Fitzgerald
Clinical Trial Grant
Respiratory
Fitzgerald
Contract
Respiratory
Fitzgerald
Contract
GlaxoSmithKline Inc. SCO 100250 BC Lung/CIHR Investigator Centers for Disease Control and Prevention 200-199-00102/ 06 Centers for Disease Control and Prevention 200-2001-00094, Task #1
Respiratory
Fitzgerald
Contract
Centers for Disease Control & Prevention 200-2001-00094, Task Order 0009
Respiratory
Fitzgerald
Contract
Respiratory
Fitzgerald
Grant
Respiratory
Fitzgerald
Grant
Respiratory
Fitzgerald
Grant
Respiratory
Fitzgerald
Grant
Centers for Disease Control and Prevention 200-2001-00094/0013, Modification #3 MSFHR: Scholar Award CI-DSH-059(03-1) CLIN MSFHR: Establishment Grant CI-DSH059(03-1)CLIN MSFHR: Matching Establishment Grant CIDSH-059(03-1)CLIN CIHR/BC Lung Assn: Investigator JBC56221
Respiratory Respiratory
Fitzgerald Fleetham
Agreement Grant
Respiratory Respiratory
Fleetham Fleetham
Grant Clinical Trial
Respiratory
Fleetham
Grant
CIHR: Randomized Controlled Trials (Clinical Trials) in collaboration with The Ottawa Health Research Institute Altana Pharma, Inc. MSFHR: Research Unit Infrastructure Support Program Various Sources BC Lung Association: Dr. W. Thurlbeck Fellowship
Respiratory Respiratory Respiratory Respiratory Respiratory Respiratory
Fleetham He Khalil Khalil Khalil Lam
Grant Grant Contract Grant Grant Clinical Trials
BC Lung Association BC Lung: Project Grant iCell Therapeutics Inc VCHRI: Interdisciplinary Grant Various Sources NIH/ NCI
UBC Department of Medicine
2005 FUNDING
$
$
$ $ $
TITLE
49,836.00 The development of a Canadian Respiratory Clinical Trials Network (D5890L00004) Comparison of Symbicort Single Inhaler Therapy (Symbicort 200 Turbuhaler 1 Inhalation bid plus as needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults: 26 Week 54,045.00 Randomized… (005-00) Double-blind, Randomized, Placebo-controlled, Multicenter Parallel-group, Dose-ranging Study of L50,635.00 000883191 in Patients with COPD Can Advair and Flovent Reduce Systemic Inflammation Related to COPD? A Multicentre, Randomized, Controlled 34,875.00 Trial (205.301) A 12-week Randomized, Double-blind, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy and 24,242.00 Safety of Inhaled Tiotropium 18 ug q.d. in Patients with COPD and a Concomitant Diagnosis of Asthma A Randomized, Double-blind, Parallel-group, 52-week Study to Compare the Effect of the Fluticasone Propionates/Salmeterol DISKUS Combination Product 250/50mcg BID with Salmeterol DISKUS 50mcg BID on the 9,611.00 Annual Rate of Moderate… 42,000.00 Bringing evidence to the patient 184,546.00 Tuberculosis Trials Consortium (TBTC)
$
82,365.00 CDC Tuberculosis Epidemiology Study Group, Task #1
$
(Task 9) Enhanced surveillance to identify missed opportunities for TB prevention in foreign-born populations in the 53,032.00 United States and Canada
$
(Task 13) Factors associated with acceptance of adherence to toxicity from treatment for Latent Tuberculosis Infection 61,969.00 (TLTBI) and pilot study of TLBI effectiveness
$
52,050.00 Bringing evidence to the patient
$
37,500.00 Bringing evidence to the patient
$
25,000.00 Bringing evidence to the patient
$
40,950.00 Bringing evidence to the patient
$ $
Optimal Therapy of COPD to Prevent Exacerbations and Improve Quality of Life: A Randomized Double-blind, 12,950.00 Placebo-controlled Trial 1,500.00 Respiratory Division Education Fund
$ $ $ $ $ $ $ $ $
150,000.00 Respiratory Sleep Disorders Research Unit 2,000.00 UBC Vancouver Hospital Respiratory Faculty Development Fund 25,000.00 The Effect of CPAP Withdrawal on Patients with Successfully Treated Obstructive Sleep Apnea Comprehensive analysis of traditional and non-traditional cardiovascular risk factors in obstructive sleep apnea 22,500.00 patients 30,000.00 Genetic control of the oxidant-antioxidant balance: Influence on lung infection in smokers 50,940.00 CRA: Transforming growth factor beta 1 regulation of vascular smooth muscle proliferation and fibrosis 10,000.00 Expression of CD36, plasminogen, and thrombospondin-1 (TSP-1) in idiopathic pulmonary fibrosis (IPF) 9,304.00 Transforming growth factor beta regulation of pulmonary fibrosis 1,366,128.00 A Phase II Trial of ACAPHA in Former Smokers with IEN
233
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION Respiratory Respiratory
RESEARCHER Lam Lam
TYPE Clinical Trials Clinical Trials
SPONSOR NIH - USA NIH - Early Detection Research Network
Respiratory
Lam
Clinical Trials
Genome Canada
2005 FUNDING TITLE $ 592,524.00 Chemoprevention of Lung Cancer $ 54,824.00 Novel Reagents and New Biomarkers in Lung Cancer Cancer Genomics: A multi-disciplinary approach to the large scale, high-throughput identification of genes involved in $ 4,200,000.00 early stage cancers
Respiratory Respiratory
Lam Lam
Clinical Trials Clinical Trials
NIH/ NCI NIC - USA
$ $
Respiratory Respiratory Respiratory
Lam Lam Lam
Clinical Trials Clinical Trials Grant
$ $ $
Respiratory
Levy
Clinical Trial
Respiratory
Levy
Grant
Respiratory
Levy
Grant
Genome Canada (* funding is over 3 years) BioEngineering Research Partnerships Vancouver General Hospital Foundation Encysive, L.P. in collaboration with Research Point BC Lung Assn: Dr. Stefan Grzybowski Fellowship (Fellow: De Jong, Pim) MSFHR: HSPR Infrastructure - Investigative Teams Prog - LOI
Respiratory
Levy
Grant
Université Laval
$
Respiratory
Levy
Clinical Trial
Actelion Pharmaceuticals Canada Inc.
$
Respiratory Respiratory
Mahmudi-Azer Man
Grant Contract
BC Lung: Project Grant GlaxoSmithKline Inc.
$ $
Respiratory
Man
Grant
MSFHR: Institutional Infrastructure Support Program $
In it for Life Mentored Clinician Scientist Award: Using location-based screening to improve tuberculosis control efforts 60,000.00 in high-risk communities of the Vancouver Coastal Health Authority
Respiratory
Man
Grant
CIHR: Operating Grant MOP-62875
$
Respiratory
Ostrow
Clinical Trial
Pfizer Canada Inc.
$
Respiratory
Ostrow
Clinical Trial
Pfizer Canada Inc.
$
33,287.00 Relationship between cardiovascular risks and systemic inflammation in chronic obstructive pulmonary disease A1481141: Multinational Multicentre Randomized Double-Blind Placebo-Controlled Parallel Group Study to Assess the Safety and Efficacy of a Subject Optimized Dose of Sildenafil (20, 40 or 80mg Sildenafil TID) based on Toleration 3,150.00 when used… A1481153: Multicenter, Multinational, Long-term, Open-label Extension Study to Assess the Safety of Subject Optimized Treatment Regimens of Oral Sildenafil When Used in Combination with Intravenous Prostacyclin 3,100.00 (epoprostenol) for Pulmonary…
Respiratory
Pare
Agreement
Ontario Genomics Institute in collaboration with: Genome British Columbia
$
68,987.00 Mapping and Isolation of Genes Influencing Severity of Disease in Cystic Fibrosis
$
$
30,909.00 Phase I Study of the Safety and Potential Efficacy of Myolnositol as a Lung Cancer Chemopreventive Agent 11,918.00 UTSW SPORE in Lung Cancer: Tissue Resources for Lung Cancer Research 6,800,000.00 Application of Pharmacogenomics for the Rational Chemotherapy of Lung Cancer 397,498.00 Optical Systems for In-vivo Molecular Imaging of Cancer 50,000.00 Detection of Early Lung Cancer by Serum Protein Expression Profiling Protocol FPH03 STRIDE III: Long-term, Open-label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in 48,521.00 Patients with Pulmonary Arterial Hypertension
$
25,000.00 Early detection of bronchiolitis obliterans following lung transplantation with high resolution CT scan imaging
$
7,500.00 COPD - net Effects of home-based vs. hospital-based outpatient pulmonary rehabilitation in patients with COPD: A multicenter, 90,000.00 randomize clinical trial A double-blind, randomized, placebo-controlled, multicentre study to assess the efficacy, safety and tolerability of 42,000.00 bosentan in patients with idiopathic pulmonary fibrosis 45,000.00 Mediator mobilization and release from neutrophil azurophillic granules in association with Asthma and COPD 177,056.00 Systemic Biomarkers in COPD
Respiratory
Pare
Grant
Heart & Stroke Foundation Canada/CIHR: Strategic Training Initiatives PG-03-0191
Respiratory
Pare
Grant
American Thoracic Society, Inc
$
36,979.00 IMPACT: Integrated and Mentored Pulmonary and Cardiovascular Training Molecular mechanisms and genetic determinants of mediator mobilization and release from neutrophil azurophilic 60,385.00 granules as it relates to COPD
$
25,000.00 Genetic Polymorphisms, Alveolar Macrophages and the Development of Emphysema
Respiratory
Pare
Grant
Respiratory
Pare
Grant
BC Lung Association - Dr. Stefan Grzybowski Fellowship (Fellow: Ishii, Takeo) MSFHR: Distinguished Scholar Award CIDSH-60(0101)
Respiratory
Pare
Grant
MSFHR: Doctoral Trainee Research Award, STPHD 12902 (Fellow: Wallace, Alison) $
UBC Department of Medicine
$
120,000.00 Molecular and Genetic Mechanisms of Obstructive Lung Disease
2,500.00 Role of Alveolar Macrophage Proteinase Genetic Polymorphisms in the Development of Emphysema
234
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION
RESEARCHER
TYPE
SPONSOR
2005 FUNDING
TITLE
Respiratory
Pare
Grant
Respiratory
Pare
Grant
CIHR/PMRF: Fellowship Awards MFE63469 (Fellow: Camp, Patricia) CIHR: Postdoctoral Fellowship GPF-69948 (Fellow: Daley, Denise)
Grant Grant
BC Lung Association: Investigator in collaboration with St. Paul's Hospital (Fellow: Sin, Don) CIHR: Operating Grant GEI-53960
$ $
32,500.00 BC Lung Association/St. Paul's Hospital Investigator Award: Dr. Don Sin 491,163.00 Inflammatory Gene Hapiotypes and Susceptibility to Cardiac, Vascular and Pulmonary Disease
$ $
273,606.00 IMPACT: Integrated and Mentored Pulmonary and Cardiovascular Training 3,000.00 Identification of therapeutic leads for hospital acquired infections
Respiratory Respiratory
Pare Pare
$ $
5,000.00 Gender Differences in Chronic Obstructive Pulmonary Disease 40,000.00 Investigation of Epistasis and Genetic Susceptibility to Hypertension in Men and Women
Respiratory Respiratory
Pare Pare
Grant Grant
CIHR/Strategic Training: Program Grant STR-63308 with HSF Canada and The Institute of Circulatory & Respiratory Health CIHR: Proof of Principle PPP-67408
Respiratory
Pare
Contract
GlaxoSmithKline Inc.
$
Respiratory
Pare
Clinical Trial
$
Respiratory
Pare
Grant
GlaxoSmithKline Inc. CIHR: Postdoctoral Fellowship GPF-69948 (Fellow: Daley, Denise)
$
Respiratory
Road
Clinical Trial
Glaxo SmithKline Inc.
$
Respiratory
Road
Clinical Trial
Altana Pharma, Inc.
$
Respiratory
Road
Clinical Trial
Altana Pharma, Inc.
$
Respiratory
Ryan
Grant
VCHRI: Interdisciplinary Grant
$
Protocol BY217/M2-118: Effect of 500 ug Roflumilast on Exercise Tolerance and Respiratory Reserve in Patients With 46,490.00 Chronic Obstructive Pulmonary Disease: A 12-Week, Double-blind Study with Roflumilast Once Daily vs Placebo (BY217/M2-121) HERO Study: A 24-week Double-blind, Randomized Study to Investigate the Effect of 500 ug Roflumilast Tablets Once Daily vs. Placebo on Parameters Indicative of Hyperinlation in Patients with Chronic 73,623.00 Obstructive Pulmonary Disease A Comprehensive Analysis of Traditional and Non-traditional Risk Factors for Cardiovascular Disease in Patients with 10,000.00 Obstructive Sleep Apnea Hypopnea (OSAH)
Respiratory
Sandford
$
15,000.00 Genetic Modifiers of Pulmonary Disease Severity in Cystic Fibrosis
Respiratory Respiratory Respiratory
Sandford Sandford Sandford
Respiratory
Sin
MSFHR Scholar Award C1-SCH-26(02-01) Canada Research Chair: Tier II (CIHR) 95001-2053 Grant Grant (iCapture) Canadian Cystic Fibrosis Foundation Grant (iCapture) BC Lung Association Canada Research Chair Tier II (CIHR) 950202044 Grant
Respiratory Respiratory Respiratory
Sin Tan Tan
Clinical Trial Grant Grant
GlaxoSmithKline Inc. Boehringer Ingelheim (Canada) Ltd. GlaxoSmithKline Inc.
$ $ $
Respiratory
Tebbutt
Grant
BC Lung: Project Grant 7568-GR0001
$
Respiratory Respiratory
Tebbutt Tebbutt
Grant Grant
$ $
Respiratory Respiratory
Ward Ward
Grant Grant
NCE/AllerGen: Research FP-2005-29 National Sanitarium Association CIHR/BC Lung Association Investigator #40941 CIHR: Operating Grant MOP-74743
UBC Department of Medicine
Grant
GSK COPD Network Patient Recontact Study: A two-year, multi-site family study to identify the genetic determinants 6,357.00 associated with susceptibility to chronic obstructive pulmonary disease 171,328.00
CRA: Develop and standardize accurate measurements of emphysema and airway wall dimensions in human lungs
5,000.00 Investigation of Epistasis and Genetic Susceptibility to Hypertension in Men and Women Protocol 207499/180: An 18-week, Randomized, Double-blind, Placebo-controlled, Multicenter Study Designed to Compare Treatment with Ariflo (Cilomilast) to that with Placebo For Changes in Ventilatory Mechanics & Function 5,776.00 (both at rest and…)
$ $ $
100,000.00 Canada Research Chair: Dr. Andrew Sandford 94,530.00 Genetic Modifiers of Disease Severity in Cystic Fibrosis 29,438.00 Genetic Determinants of Neutrophil Mediator Mobilization, Release and Susceptibility to COPD
$
100,000.00 Canada Research Chair in Chronic Obstructive Pulmonary Disease for Dr. Don Sin IICT: Can Advair and Flovent Reduce Systemic Inflammation Related to COPD? A Multicentre, Randomized, 701,004.00 Controlled Trial 220,000.00 The Burden of Chronic Obstructive Lung Disease (BOLD) Study 156,667.00 BOLD STUDY: The Burden of Chronic Obstructive Lung Disease
$ $
17,000.00 Detection of population stratification within lung health study cohort using microarray genotyping and genomic control AllerChip - Development, Validation and Implementation of a Microarray Genotyping Tool for Allergy and Asthma 25,000.00 Research 325,000.00 Real-time Clinical Genomics in Pulmonary Medicine 10,238.00 Occupational Health Risks in the Health Care Industry 81,531.00 A cohort study of nurses' offspring examining adverse reproductive effects and childhood cancer
235
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006 DIVISION
RESEARCHER
TYPE
SPONSOR
2005 FUNDING
TITLE A randomized, double-blind, placebo-controlled, phase 3 study of the safety and efficacy of Interferon Gamma-1b in patients with idiopathic pulmonary fibrosis (The INSPIRE Trial: International Study of Survival Outcomes in IPF with Interferon) A Phase 3, Double-blind, Multicenter, Multinational, Randomized, Placebo-controlled Trial Evaluating Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients with P. Aeruginosa (AIR-CF1) DPM-CF-202: A Phase 2A, Randomised, Open-label, Dose-response Study to Determine the Optimum Dose of Dry Powder Mannitol Required to Generate Clinical Improvement in Patients with Cystic Fibrosis Pleural Disease Initiative
Respiratory
Wilcox
Clinical Trial
Intermune Pharmaceuticals, Inc.
$
36,879.00
Respiratory
Wilcox
Clinical Trial
Corus Pharma Inc.
$
9,418.00
Respiratory Respiratory
Wilcox Wilson
Clinical Trial Grant
Pharmaxis Ltd. Vancouver Coastal Health Authority
$ $
2,799.00 50,000.00
Rheumatology
Choi
Grant
$
Rheumatology
Cibere
Grant
$
40,000.00 Research Allowance: Development of a Model for the MRI Progression of Knee Osteoarthritis
Rheumatology Rheumatology Rheumatology
Cibere Cibere Esdaile
Grant Clinical Trial Grant
Department of Medicine CIHR Clinician Scientist MC2-69188 Phase 2 CIHR Clinician Scientist MC2-69188 Phase 2 Hecht Foundation Arthritis Society: TAS00/0190,88062
$ $ $
58,500.00 Development of a Model for the MRI Progression of Knee Osteoarthritis 39,165.00 A randomized, double-blind, placebo-controlled trial of tryterygium wilfordii in rheumatoid arthritis 35,000.00 UBC Rheumatic Disease Unit
Rheumatology Rheumatology Rheumatology Rheumatology Rheumatology Rheumatology
Esdaile Esdaile Lacaille Lacaille Shojania Tsang
Grant Grant Grant Grant Grant Clinical Trial
CIHR/Strategic- Request for Applications NCE/CAN Research NCE/CAN TAS/CIHR TAS Hecht Foundation
$ $ $ $ $ $
150,000.00 150,000.00 44,250.00 50,000.00 45,000.00 39,165.00
TOTAL: $
52,289,142.00
UBC Department of Medicine
150,000.00 Laboratory start-up funds
236
Tooling Up for OA: Measuring What Matters Tooling Up for OA: Measuring What Matters Assessing the quality of care for rheumatoid arthritis (RA) at a population level New Investigator Award Clinical Teacher Award A randomized, double-blind, placebo-controlled trial of tryterygium wilfordii in rheumatoid arthritis
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
237
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
238
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
239
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
240
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
241
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
242
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
243
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
244
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
245
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
246
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
247
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
248
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
249
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
250
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
251
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
252
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
253
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
254
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
255
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
256
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
257
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
258
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
259
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
260
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
261
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
262
Annual Report 2005
UBC DEPARTMENT OF MEDICINE AWARDS BY DIVISION FOR 2005 - 2006
UBC Department of Medicine
263
Annual Report 2005
